

PATENT
830010-2002.2
09/975,812

REMARKS

Claims 11, 16-20, and 22-26 are pending in the instant application. Claims 16 and 22 have been cancelled, without prejudice to Applicants' right to pursue the subject matter of the claims in this or related applications. Claim 11 has been amended to clarify the subject matter of the present invention and to round out the scope of protection to which Applicants are entitled; i.e., the claim amendment was not made for the purpose of patentability within the meaning of 35 U.S.C. §§ 101, 102, 103, or 112. Reconsideration and withdrawal of all rejections of the application, and allowance of the claims, especially in view of the amendments and remarks made herein and the documents herewith, are respectfully requested.

The previous response, filed on November 27, 2002, reviewed the contrast between the present invention and the state of the art at the time the instant application was filed. The potential for peripheral mechanisms to play a significant role in the mediation of antinociceptive responses was unknown prior to the teaching of the present invention. Opioid analgesia was thought to be mediated through the central nervous system (i.e., systemically) rather than through peripheral opioid receptors. Those skilled in the art did not appreciate the significance of peripheral opioid receptor stimulation, much less the significance of combining opioid analgesics and local anesthetics at these peripheral sites. Methods of the present invention comprising topical administration of opioid analgesics and local anesthetics unexpectedly produce synergistic pain relief in the periphery, even in small, non-systemic dosages ranges.

In response, the Office Action of February 26, 2003 asserts that claimed invention is obvious under 35 U.S.C. § 103(a) in view of the combination of Stein (U.S. Patent No. 5,948,389) and Saito et al. Stein involves administration of topical compositions comprising opioid analgesics and/or local anesthetics that must be contained in hyperosmolar solutions. Saito reports that systemic administration of morphine and lidocaine—at dosages outside of the claimed ranges—produces a synergistic antinociceptive response in rats. The Office Action correctly states that Stein and Saito, taken together, do not teach the employment of a single composition comprising both morphine and lidocaine. However, the Office Action then states that administration of a topical composition comprising both drugs would have been obvious to one of ordinary skill in the art on the basis of the cited documents. The cited documents do not teach or suggest the claimed methods because, inter alia:

PATENT
830010-2002.2
09/975,812

- Concentrations of morphine and/or lidocaine that are said to be synergistic do not fall within the scope of the claims and therefore, have no bearing on the efficacy of the claimed compositions.
- There is no teaching or suggestion of a topical composition acting solely in the periphery, much less one having synergistic effects.

In addition to the challenges made to the cited documents herein, the position of the Office is now rebutted by further evidence of non-obviousness. The data contained in the instant application was published in the Journal of Pharmacology and Experimental Therapeutics ("the Journal"). See Kolesnikov et al., (2000) J. Pharm. Exp. Therapeutics, Vol. 295 (2), which is submitted concurrently in the accompanying Supplemental Information Disclosure Statement as reference AQ. Submitted herewith is the declaration of Sandra C. Roerig, Ph.D. under 37 C.F.R. § 1.132, editor for the Journal, forwarding the statements of reviewers for the Journal who analyzed the data of the instant application on May 19, 2000 and found the results to be unexpected. It is respectfully submitted that the Office Action employs an improper hindsight combination of cited documents and an artificial view of the art. Moreover, it is respectfully asserted that the combination of documents and views in the Office Action are clearly and convincingly overcome by actual statements by those skilled in the art attesting to the surprising nature of the claimed methods.

Also submitted herewith is a copy of Exhibit A to accompany the Declaration filed on December 2, 2002 under 37 C.F.R. § 1.131.

RAM Fee History
Query
Revenue Accounting and Management

Name/Number: 09975812

Total Records Found: 8

Start Date: Any Date

End Date: Any Date

Accounting Date	Sequence Num.	Tran Type	Fee Code	Fee Amount	Mailroom Date	Payment Method
10/16/2001	00000075	<u>1</u>	<u>201</u>	\$370.00	10/11/2001	CK
10/16/2001	00000076	<u>1</u>	<u>203</u>	\$135.00	10/11/2001	CK
11/21/2001	00000003	<u>6</u>	<u>605</u>	\$90.00	11/21/2001	ET
11/21/2001	00000002	<u>1</u>	<u>203</u>	\$45.00	10/11/2001	CK
11/21/2001	00000001	<u>1</u>	<u>203</u>	-\$135.00	10/11/2001	OP
04/10/2002	00000057	<u>1</u>	<u>126</u>	\$180.00	04/05/2002	CK
12/03/2002	00000241	<u>1</u>	<u>2801</u>	\$370.00	12/02/2002	CK
06/27/2003	00000006	<u>1</u>	<u>2251</u>	\$55.00	06/25/2003	CK

PATENT
830010-2002.2
09/975,812

THE REJECTIONS UNDER 35 U.S.C. § 112, FIRST PARAGRAPH ARE OVERCOME

Applicants respectfully traverse the rejections of claims 11, 16-20, and 22-26 under 35 U.S.C. 112, first paragraph, as allegedly containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The Examiner alleges that the particular limitation in claim 11, "to potentiate a synergistic antinociceptive response at peripheral sites" lacks support from the specification or claims as originally filed.

In response, Applicants respectfully direct the Examiner to page 19, lines 6-8, 12-14, and 20-22 of the specification as originally filed. The specification clearly recites on page 19, lines 6-8 that "[s]ynergistic potentiation of analgesia through topical administration of a local anesthetic/opioid combination offers a new approach to peripheral pain management". The specification also recites on page 19, lines 12-14 that "[i]t has now been found that topical administration of a composition comprising certain relative amounts of opioids and local anesthetics results in the synergistic potentiation of peripheral antinociceptive responses". Furthermore, the specification utilizes the terminology "potentiated antinociceptive response" as "a pain-reducing response elicited through the synergistic effect of at least one opioid and at least one local anesthetic, in which the combined effect is greater than the sum of the effect produced by either agent alone". Thus, Applicants respectfully submit that the particular limitation in claim 11, "to potentiate a synergistic antinociceptive response at peripheral sites" is unambiguously supported in the specification as originally filed and respectfully request withdrawal of the rejection under 35 U.S.C. § 112, first paragraph.

THE REJECTIONS UNDER 35 U.S.C. § 103 ARE OVERCOME

Applicants respectfully traverse the rejections of claims 11, 16-20, and 22-26 under 35 U.S.C. § 103, in view of Stein and Saito. The cited documents, taken alone or together, fail to teach or suggest methods of administering the topical compositions of the present invention.

The claimed methods relate to the administration of topical compositions having a concentration of morphine from about 0.01% to about 25% and the concentration of lidocaine from about 0.01% to about 25%. The exemplary concentrations of morphine and/or lidocaine in the cited documents do not fall within the scope of the claims and therefore, have no bearing on

PATENT
830010-2002.2
09/975,812

the efficacy of, and fail to teach or suggest, the claimed methods. Moreover, the cited documents fail to teach or suggest a topical composition acting solely in the periphery, much less one having synergistic effects.

U.S. Patent No. 5,948,389 ("Stein")

The Stein patent is directed to topical administration of hyperosmolar solutions of opioids or anesthetics (or mixtures) such that the drugs first pass into non-inflamed tissue in order to reach inflamed tissue. Stein does not teach or suggest administration of topical compositions having only local effects in the periphery, or the benefit thereof. This marks a clear distinction between Stein and the present invention.

Importantly, Stein does not teach or suggest that there is a synergistic effect between opioid analgesics and local anesthetics at peripheral sites, which is an unexpected result of the present invention. In fact, Stein does not teach that use of two agents in combination would be any better than the use of a single agent alone, much less synergistic.

Stein states only that a range between 0.5% and 95% (w/v) of drug in solution of osmolality between 300-700 mOsm/L can be used. No exemplification of lidocaine or morphine is provided. Therefore, the skilled artisan would have no reasonable expectation that a topical combination of lidocaine and morphine in the claimed dosage ranges would have a synergistic effect. Saito also fails to teach synergy in the claimed dosage ranges; and, as a result, the combination of the documents employed in the Office Action fails to cure the deficiencies of both Stein and Saito to teach or suggest the instant invention.

Applicant's previous response, filed on November 27, 2002, presented several studies which demonstrated that the topical administration of morphine was discouraged in a clinical setting. The Office Action relies upon Stein to allegedly define the state of the art at the time the instant application was filed. It is compelling that that Stein provides no exemplification whatsoever for the use of topical morphine. As such, Stein does not carry sufficient weight to reverse the well established and widely held view in the art that topical morphine is not an effective pain reliever.

The response filed on November 27, 2002 presented information relating to hundreds of patients who failed to receive any benefit from morphine treatment at peripheral sites. *See*

PATENT
830010-2002.2
09/975,812

Moore et al.¹ (describing two consecutive studies on twenty patients treated with a topical morphine gel); Raja et al.² (describing a randomized, double-blinded study comparing the analgesic efficacy of bupivacaine and morphine administered intraarticularly in 47 patients having undergone arthroscopic knee surgery); Rosenstock et al.³ (describing a double-blind, randomized, placebo-controlled study to evaluate the possible immediate and long-term analgesic effect of morphine injected incisionally in patients undergoing minor abdominal surgery); Picard et al.⁴ (reviewing 26 randomized controlled trials studied 925 patients, of which 485 received peripherally-acting opioids, including morphine, fentanyl, alfentanil, buprenorphine and butorphanol); Yarussi et al.⁵ (describing a study to evaluate the post-operative analgesic effects of incisionally-administered morphine in 45 patients undergoing lumpectomies and axillary node dissections in the treatment of breast cancer).

Therefore, contrary to the position of the Office, Stein does not outweigh prior teachings in the art that discourage the use of topical morphine in among a great number of patients.

Saito et al.

Saito teaches the intrathecal (i.e. systemic), but not topical, administration of an opioid in combination with an anesthetic, whereby such co-administration leads to a synergistic analgesic effect. The teaching of a systemic administration of an opioid is contrary to the instant invention. At best, Saito continues to emphasize the views of those skilled in the art—that analgesic actions are mediated through the central nervous system. Nowhere in Saito is it suggested that combinations of analgesics and local anesthetics can synergistically stimulate peripheral sites.

When morphine and lidocaine were administered together in Saito, the following concentrations (in percent w/v) were used: 0.12% morphine (0.3 µg/kg/h in 250 µl volume) and 80% lidocaine (200 µg/kg/h in 250 µl volume); 1.2% morphine (3 µg/kg/h in 250 µl) and 12%

¹ Moore UJ, Seymour RA, Gilroy J, Rawlins MD. (1994) "The Efficacy of Locally Applied Morphine In Post-Operative Pain After Bilateral Third Molar Surgery," Br. J. Clin. Pharmacol. 37:227-30.

² Raja SN, Dickstein RE, Johnson CA. (1992) "Comparison of Postoperative Analgesic Effects of Intraarticular Bupivacaine and Morphine Following Arthroscopic Knee Surgery," Anesthesiology 77:1143-7.

³ Rosenstock C, Andersen G, Antonsen K, Rasmussen H, Lund C. (1996) "Analgesic Effect of Incisional Morphine Following Inguinal Herniotomy Under Spinal Anesthesia," Reg. Anesth. 21:93-8.

⁴ Picard PR, Tramer MR, McQuay HJ, Moore RA. (1997) "Analgesic Effect of Peripheral Opioids (all except intra-articular): A Qualitative Systematic Review of Randomised Controlled Trials" Pain 72:309-18.

PATENT
830010-2002.2
09/975,812

lidocaine (30 µg/kg/h). **Only the combination of 1.2% morphine and 12% lidocaine falls within the scope of the claims. The results reported by Saito in this range were not shown to be greater than additive, i.e., not synergistic.**

Only the Saito abstract was cited against the instant application.⁶ Upon examination of the article in full text, it is apparent that the authors do not conclude that the combination of 1.2% morphine and 12% lidocaine produces a synergistic response. The Examiner's attention is respectfully directed to Figure 4 of the Saito reference, depicting the time course effects of 1.2% morphine (3 µg/kg/h in 250 µl) and 12% lidocaine (30 µg/kg/h), administered by intrathecal infusion. No further analysis of this combined dosage was performed and therefore, no synergy was reported.

Measurement of synergy in Saito is performed by isobolographic analysis (Figure 5), using three dose-effect curves: one for morphine, one for lidocaine and one for the combination at a fixed dosage having a morphine:lidocaine ratio of 1:200. *See Saito*, page 1457 (stating "[t]o perform isobolographic analysis, the dose ratio of the combination was fixed at a morphine:lidocaine ratio of 1:200") and page 1458 under "*Isobolographic Analysis*." Combination doses outside of the claimed dosage ranges were used in the isobolographic analysis (i.e., between 30 µg/kg/h and 600 µg/kg/h lidocaine). **Therefore, the isobolographic analysis in Saito does not show that the combination of 1.2% morphine (3 µg/kg/h in 250 µl) and 12% lidocaine (30 µg/kg/h) produces a synergistic effect.**

Accordingly, the authors state only that the higher combination of 0.12% morphine and 80% lidocaine "may indicate synergistic antinociceptive effects." *See Saito*, page 1460. Moreover, the authors do not find these results to be relevant to any other dosage range or mode of administration, stating "[t]he magnitude of the synergistic effects depends on the concentration of infused drugs when the infusion is constant." *Id.* Therefore, Saito does not teach or suggest synergy in the claimed dosage ranges.

Finally, nowhere in Saito is it demonstrated or suggested that the observed antinociceptive effects occur at peripheral sites. The authors carefully define the limits of their

⁵ Yarussi A et al. (1999) "Evaluation of Peripheral Morphine Analgesia for Lumpectomy and Axillary Node Dissection: A Randomized, Double-blind, Placebo-controlled Study," *Reg. Anesth. Pain. Med.* 24:142-5.

⁶ It is respectfully noted that the Board of Patent Appeals and Interferences has admonished the Examining Corps to not cite only abstracts of documents in making rejections. *See Ex Parte Jones*, 62 U.S.P.Q. 1206 (Pat. & Tr. Office Bd. App. 2001).

PATENT
830010-2002.2
09/975,812

study, stating that morphine and lidocaine were selected to "evaluate the antinociceptive interaction of opioid and local anesthetics at the spinal level..." See Saito, page 1461 (emphasis added). At the time the instant application was filed, a showing of antinociception by a composition acting in the central nervous system had no bearing on its potential for action in the periphery, and nothing in Saito suggests otherwise. Thus, Saito, like Stein, does not teach or suggest topical compositions having only local effects in the periphery, or the benefit thereof.

Given the lack of exemplification in Stein, the lack of relevant synergistic efficacy in Saito, and the failure of both references to disclose or suggest compositions having a localized topical effect, it is respectfully submitted that the cited documents fail to teach or suggest the claimed methods. Reconsideration and withdrawal of the rejections under 35 U.S.C. §103(a) is respectfully requested.

Declaration of Sandra Roerig, Ph.D. Under 37 C.F.R. § 1.132

Submitted herewith is the declaration of Sandra C. Roerig, Ph.D. under 37 C.F.R. § 1.132, as editor for the Journal of Pharmacology and Experimental Therapeutics ("the Journal"). The data contained in the instant application was published in the Journal. Dr. Roerig attests to the May 19, 2000 statements of reviewers for the Journal who in the ordinary course of business analyzed the data of the instant application (e.g., depicting the synergistic effect of topical compositions of morphine and lidocaine in mice) and found the results to be unexpected. Specifically, the reviewers found that the synergy produced by the claimed methods was "profound" and "quite marked." One of the reviewers further stated that studies of this kind had "never been performed previously." It was their view, as communicated by Dr. Roerig, that the results were unexpected and therefore, non-obvious.

The statements of the reviewers are in contrast to the position of the Office, which is stated as follows on pages 3-4 of the Office Action:

A person of ordinary skill in the art would have been motivated to make and use a topical composition, which comprises morphine and lidocaine because lidocaine and morphine in combination are known to provide synergistic antinociceptive effects, and because they are known to be employed in combination.

Prior to the teaching of the present application, morphine and lidocaine were not known to synergistically potentiate the antinociceptive effects of each other in the periphery. The extent

PATENT
830010-2002.2
09/975,812

to which they interact in the periphery, as first shown by the Applicants, was stated to be "profound" and "quite marked" by those skilled in the art. In this regard, the claimed methods exhibit unexpected and surprising effects.

The Office Action further states on page 4:

[I]ntraconversion of dosage forms of optimization of the effective amounts of each ingredient to provide a known synergistic effect are within the skill of the artisan and therefore obvious. Regarding the particular limitation about the sites of synergistic antinociceptive response, note since the references teach synergistic antinociceptive effects generally, and would encompass any synergistic antinociceptive response.

Stein does not teach topical compositions having only local effects in the periphery, nor does Stein teach topical application of morphine or lidocaine in the claimed dosage ranges with any reasonable expectation of success. Any reasonable expectation of success could not come from the teaching of Stein and Saito, and the general knowledge in the art, but rather could only come from the teaching of the present invention. Optimization of synergistic amounts for topical application in the periphery was not a matter of routine variation based on existing art and in no way expected, as stated by the Journal reviewers. This position is further supported by Saito, which also emphasizes the importance of sufficient drug concentration in achieving synergy. *See* Saito, page 1460.

It is impermissible to engage in a hindsight reconstruction of the claimed invention, using the Applicant's structure as a template, and selecting elements from references to fill in the gaps. *Interconnect Planning*, 744 F.2d 1132, 1143 (Fed. Cir. 1985). Only through the exercise of impermissible hindsight have the cited references (i.e., Saito and Stein) been selected and relied upon by the Office. Systemic combinations of opioids and analgesics are non-analogous art, having no bearing on the function of topical compositions providing only localized effects in the periphery. As such, the skilled artisan working to develop a localized peripheral pain reliever and methods of its use is not motivated by literature describing systemic responses.

The view of the art allegedly conveyed by the cited references is unequivocally overcome by actual statements made by those skilled in the art attesting to the surprising nature of the claimed compositions. Withdraw of all rejections under 35 U.S.C. § 103(a) is requested.

PATENT
830010-2002.2
09/975,812


REQUEST FOR INTERVIEW

If any issue remains as an impediment to allowance, a further interview with the Examiner and SPE are respectfully requested; and, the Examiner is additionally requested to contact the undersigned to arrange a mutually convenient time and manner for such an interview.

In view of the declaration and remarks herewith, the application is in condition for allowance. Favorable reconsideration of the application and prompt issuance of a Notice of Allowance are earnestly solicited. The Commissioner is hereby authorized to charge any additionally required fee occasioned by this paper, or credit any overpayment in this case, to Deposit Account No. 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By:



Amy Leaky
Reg. No. 47,739
William F. Lawrence
Reg. No. 28,029
(212) 588-0800

Intellectual Property Library

ISSN 1526-8535

FULL TEXT OF CASES (USPQ2D)
Cases Publishing the Week of Apr 15, 2002

**(Unpublished) Ex parte Jones, 62 USPQ2d 1206
(BdPatApp&Int 2001)**



Appeal No. 2001-1839
Decided November 28, 2001

Unpublished Opinion

(Non-precedential)

Headnotes

PATENTS

**[1] Patentability/Validity — Obviousness — Combining references
(§115.0905)**

“Motivation” to combine teachings of prior art is not always required to support obviousness rejection under 35 U.S.C. §103, since legally sufficient rationale for finding of obviousness may be supported by reason or suggestion in prior art, as well as motivation, to combine teachings.

**[2] Practice and procedure in Patent and Trademark Office —
Board of Patent Appeals and Interferences — Rules and rules**

Intellectual Property Library

ISSN 1526-8535

practice (§110.1105)

Patentability/Validity — Obviousness — Relevant prior art — In general (§115.0903.01)

Patent examiner's citation of abstract in support of rejection without citation and reliance on underlying scientific article is generally inappropriate if both abstract and underlying document are prior art, and proper examination therefore should be based on underlying documents and translations, if necessary, since abstracts often are not written by author of underlying document, and may be erroneous; in present case, in which neither examiner nor applicant relies on underlying articles, Board of Patent Appeals and Interferences, in exercise of its discretion, will not obtain translations of underlying journal articles in order to evaluate merits of translations in first instance, since it is examiner's responsibility to obtain translations, and since review of translations by examiner and applicant may supply additional evidence as to whether there is legally sufficient reason, suggestion, teaching, or motivation to combine teachings of cited articles, and thus may eliminate need for appeal.

Case History and Disposition

Patent application of Jones, serial no. 08/947,428.1 Applicant appeals from examiner's rejection of claims 38 and 39 in application. Vacated and remanded.

[Editor's Note: The Board of Patent Appeals and Interferences has indicated that this opinion is not binding precedent of the board.]

Judge:

Before Winters and William F. Smith, administrative patent judges, and McKelvey, senior administrative patent judge.

Footnotes

1 Application for patent filed 8 October 1997.

Opinion Text

Opinion By:
McKelvey, S.J.

***Decision on appeal under
35 U.S.C. § 134***

[Unpublished] The appeal is from a decision of a primary examiner rejecting claims 38-39. We vacate and remand for action not inconsistent with views expressed herein.

A. Findings of fact

[Unpublished] The record supports the following findings by at least a preponderance of

Intellectual Property Library

ISSN 1526-8535

the evidence.²

[Unpublished] 1. The claimed invention relates to a method of making organic chemicals.

[Unpublished] 2. The examiner has rejected claims 38-39 as being unpatentable under 35 U.S.C. §103(a) over

Page 1207

[Unpublished] a) Horner,
[Unpublished] b) Suri,
[Unpublished] c) Endel'man,
[Unpublished] d) Manthey and
[Unpublished] e) Ota.

[Unpublished] 3. Horner is a 25-page technical journal article written in German.

[Unpublished] 4. The examiner has placed in the record a short English-language abstract of Horner.

[Unpublished] 5. The record does not contain an English-language translation of Horner.

[Unpublished] 6. Suri is a 2-page technical journal article written in English.

[Unpublished] 7. Endel'man is a 4-page technical journal article written in Russian.

[Unpublished] 8. The examiner has placed in the record a short English-language abstract of Endel'man.

[Unpublished] 9. The record does not contain an English-language translation of Endel'man.

[Unpublished] 10. Manthey is a 5-page technical journal article written in English.

[Unpublished] 11. Ota appears to be a 5-page technical journal article written in Japanese.

[Unpublished] 12. The examiner has placed in the record a short English-language abstract of Ota.

[Unpublished] 13. The record does not contain an English-language translation of Ota.

[Unpublished] 14. The examiner does not maintain that any one of the five prior art references fully describes the claimed invention. Hence, a rejection based on 35 U.S.C. §103(a).

[Unpublished] 15. According to the examiner, "the skilled artisan looking for an alternative route for the preparation" of the product produced by the claimed method "was deemed to be aware of all the various methods of the preparation" of the product (Examiner's Answer, page 4).

[Unpublished] 16. Further according to the examiner, "one of ordinary skill in the art would be motivated [sic—would have been motivated] to prepare *** [the compound made by applicant's claimed method] by coupling Suri's *** acid and Endel'man's *** acid as taught by Manthey followed by *** [further treatment] to yield *** [a compound] as taught by Horner and subsequent reduction as taught by Ota to arrive at the *** [claimed process]" (Examiner's Answer, pages 4-5).

[Unpublished] 17. According to applicant, the requisite "motivation" is not present in the prior art because "[t]hroughout the prosecution the examiner has failed to point out any teaching or suggestion in the prior art that would motivate the skilled artisan" to use the claimed process invention (Appeal Brief, page 4).

Intellectual Property Library

ISSN 1526-8535

B. Discussion

1. Rationale in support of obviousness

[Unpublished]

[1] The applicant and the examiner have apparently assumed that there always must be "motivation" to combine teachings of the prior art to support a rejection based on §103(a). The assumption is not correct. The word "motivation" or a word similar to "motivation" does not appear in 35 U.S.C. § 103(a). While a finding of "motivation" supported by substantial evidence probably will support combining teachings of different prior art references to establish a *prima facie* obviousness case, it is not always necessary. For example, where a claimed apparatus requiring Phillips head screws differs from a prior art apparatus describing the use of flathead screws, it might be hard to find motivation to substitute flathead screws with Phillips head screws to arrive at the claimed invention. However, the prior art would make it more than clear that Phillips head screws and flathead screws are viable alternatives serving the same purpose. Hence, the prior art would "suggest" substitution of flathead screws for Phillips head screws albeit the prior art might not "motivate" use of Phillips head screws in place of flathead screws.

[Unpublished] What must be established to sustain an obviousness rejection is a legally sufficient rationale as to why the claimed subject matter, as a whole, would have been obvious notwithstanding a difference between claimed subject matter and a reference which is prior art under 35 U.S.C. § 102. Once a difference is found to exist, then the examiner must articulate a legally sufficient rationale in support of a §103(a) rejection. The legally sufficient rationale may be supported by a reason, suggestion, teaching or motivation in the prior art which would have rendered obvious the claimed subject within the meaning of § 103(a). *In re Dance*, 160 F.3d 1339, 1343, 48 USPQ2d 1635, 1637 (Fed. Cir. 1998) (there must be some *teaching, suggestion or motivation* in the prior art to make the specific combination that was made by the applicant); *In re Gartside*, 203 F.3d 1305, 1319, 53 USPQ2d 1769, 1778 (Fed. Cir. 2000) (the best defense against the subtle but powerful attraction of a hindsight-based obviousness analysis is rigorous application of the requirement for a *teaching or motivation* to combine prior art references); *Pro-Mold and Tool Co. v. Great Lakes Plastics Inc.*

Page 1208

, 75 F.3d 1568, 1573, 37 USPQ2d 1626, 1629 (Fed. Cir. 1996) ("there must be a *reason, suggestion, or motivation* *** to combine [the teachings of] *** references ***"); *Smiths Industries Medical Systems, Inc. v. Vital Signs, Inc.*, 183 F.3d 1347, 1356, 51 USPQ2d 1415, 1420-21 (Fed. Cir. 1999) (there is no basis for concluding that an invention would have been obvious solely because it is a combination of elements that were known in the art at the time of the invention; the relevant inquiry is whether there is a *reason, suggestion, or motivation* in the prior art that would lead one of ordinary skill in the art to combine the teachings of the references).

[Unpublished] Moreover, when an examiner maintains that there is an explicit or implicit teaching or suggestion in the prior art, the examiner should indicate where (page and line or figure) such a teaching or suggestion appears in the prior art. *In re Rijckaert*, 9 F.3d 1531, 1533, 28 USPQ2d 1955, 1957 (Fed. Cir. 1993), citing *In re Yates*, 663 F.2d

Intellectual Property Library

ISSN 1526-8535

1054, 1057, 211 USPQ 1149, 1151 (CCPA 1981).

[Unpublished] One difficulty with the rationale in support of the examiner's rejection in this case, and for that matter the applicant's challenge to the rejection, is that it appears to be based solely on a motivation rationale without taking into account whether there otherwise is a legally sufficient *reason, showing, suggestion or teaching* which might also suffice to support the examiner's rejection. Moreover, a suggestion, teaching or motivation to combine teachings of the prior art may flow from the prior art references themselves, the knowledge of one of ordinary skill in the art, or, in some cases, from the nature of the problem to be solved. *In re Dembiczak*, 175 F.3d 994, 999, 50 USPQ2d 1614, 1617 (Fed. Cir. 1999). *See also In re Gartside, supra* at 1319, 53 USPQ2d at 1778 (the suggestions may come from, *inter alia*, the teachings of the references themselves and, in some cases, from the nature of the problem to be solved).

[Unpublished] If the examiner determines that it is appropriate to enter a further rejection, the examiner may wish to consider a rationale based on a suggestion, teaching or other reason in place of a rationale based exclusively on motivation.

[Unpublished] We will also note that the examiner's theory of rejection, at least in part, seems to rely on the proposition that if a person of ordinary skill in the art is looking for an alternative method for the preparation of a compound, then that person would be aware of all analogous art (see Finding 15). If the examiner continues to rely on that theory, then the examiner would be under a burden to establish why a person of ordinary skill in the art would be looking for an alternative method, particularly where a method is known for making a particular compound.

2. Use of abstracts in place of underlying articles

[Unpublished] The principal difficulty with the prosecution of the application on appeal is the examiner's attempt to establish "motivation" by reliance on three English-language abstracts of journal articles written in foreign languages. The examiner does not maintain that only Suri and Manthey, both in English, support the rejection. The use of abstracts, when the underlying document is prior art, gives us considerable pause.

[Unpublished] The Board of Patent Appeals and Interferences continues to have recurring problems in resolving *ex parte* appeals which come before it. One continuing recurring problem is the citation and reliance by examiners on abstracts, without citation and reliance on the underlying scientific document.

[Unpublished]

[2] In this appeal, the examiner relied upon abstracts of three technical journal articles without referring to translations of the underlying documents. Citation of an abstract without citation and reliance on the underlying scientific document itself is generally inappropriate where both the abstract and the underlying document are prior art.

Abstracts often are not written by the author of the underlying document and may be erroneous. It is our opinion that a proper examination under 37 CFR § 1.104 should be based on the underlying documents and translations, where needed. Accordingly, the preferred practice is for the examiner to cite and rely on the underlying document.

[Unpublished] When an examiner cites and relies only on an abstract, the applicant may wish to obtain a copy of the underlying document and submit a copy to the examiner when responding to a rejection relying on an abstract. In the event a reference is in a foreign language, if the applicant does not wish to expend resources to obtain a

Intellectual Property Library

ISSN 1526-8535

translation, the applicant may wish to request the examiner to supply a translation. If

Page 1209

a translation is not supplied by the examiner, the applicant may wish to consider seeking supervisory relief by way of a petition (37 CFR § 1.181) to have the examiner directed to obtain and supply a translation.

[Unpublished] In the past, when neither the examiner nor the applicant relies on the underlying article, the board often expended the resources necessary to obtain a copy of the underlying scientific article, as well as translations thereof. When it did so, however, the burden of examining the application fell on the board in the first instance. Moreover, to the extent that the board relies on parts of a translation not previously provided to an applicant, any affirmance generally has to be a new ground of rejection under 37 CFR § 1.196(b)—which can result in further prosecution.

[Unpublished] In this case, we do not know whether the examiner or the applicant had or reviewed the underlying foreign language technical journal articles or translations thereof. The board cannot examine, in the first instance, all applications which come before it in an *ex parte* appeal under 35 U.S.C. § 134. In this particular appeal, we exercise discretion by declining to obtain translations of the underlying technical journal articles and thereafter evaluate on the merits in the first instance the translations. In our view, obtaining translations is the responsibility of the examiner. A review by the examiner and applicant of translations of the prior art relied upon in support of the examiner's rejection may supply additional relevant evidence as to whether there is a legally sufficient reason, suggestion, teaching or motivation to combine the teachings of the five technical journal articles. Moreover, an evaluation of translations may eliminate the need for an appeal.

C. Decision

[Unpublished] The decision of the examiner rejecting claims 38-39 under 35 U.S.C. § 103(a) over (1) Horner, (2) Suri, (3) Endelman, (4) Manthey and (5) Ota is *vacated* and the application is *remanded* to the examiner. For the effect of a decision vacating an examiner's rejection, see *In re Zambrano*, 58 USPQ2d 1312 (Bd. Pat. App. & Int. 2001) (explaining that vacated rejection no longer exists).

[Unpublished] The examiner and/or the applicant may obtain translations of (A) Horner, (B) Endelman and (C) Ota.

[Unpublished] Nothing in this opinion should be read as precluding the examiner from entering a rejection based on translations. In the event the examiner determines that claims 38-39 are unpatentable over the combination of the five references (or any additional prior art), then the examiner must identify and cite the specific portions (page and line or figure) of each article or prior art document upon which he relies in support of any rejection. We are primarily a board of review. Accordingly, neither the examiner nor applicant should expect in any further appeal for us to dig through five prior art references to come up with a theory which might support or negate a rejection in the first instance. Moreover, if the examiner enters a further rejection based on foreign language document, translations must be obtained if a further appeal is taken. We will not decide a further appeal without translations.

[Unpublished] We express no views on the ultimate merits of any rejection under 35 U.S.C. § 103(a) based on the five prior art references or any additional prior art which the

Intellectual Property Library

ISSN 1526-8535

examiner and applicant may wish to make of record.

D. Order

[Unpublished] Upon consideration of the appeal, and for the reasons given, it is
[Unpublished] ORDERED that the examiner's rejection under §103(a) of claims 38-39 is
vacated.

[Unpublished] FURTHER ORDERED that the application is *remanded* to the examiner
for action not inconsistent with the views expressed in this opinion.

[Unpublished] FURTHER ORDERED that no time period for taking any subsequent
action in connection with this appeal may be extended under 37 CFR § 1.136(a).

VACATED and REMANDED

Footnotes

2 To the extent these findings of fact discuss legal issues, they may be treated as
conclusions of law.

- End of Case -

Exhibit A

01/19/04 FRI 10:42 FAX 212 111 3439

1 5 8 0 0

Memorial Sloan-Kettering Cancer Center
INVENTION DISCLOSURE FORMFile No. SK 901

(File No. completed by Office of Industrial Affairs)

This form is provided to help organize your thoughts about your invention. Be careful to describe what, specifically, makes your invention different from what has been invented before. Avoid general statements that your invention is "Better" - why is it better, or what makes it better?

Descriptive Title of Invention:***2) Description of Invention:***

Topical treatments of pain by combination of local anesthetics, opioids, alpha-adrenergic and imidazoline receptors agonists

a) State as fully as possible, what the invention is, including:

The demonstration of utility of topical combination of local anesthetics, clonidine, agmatine and opioids for the relief of acute and peripheral neuropathy without systemic absorption and ability of clonidine and agmatine synergistically potentiate of lidocaine analgesia in this paradigm, as well as clonidine and agmatine utility alone as analgesics.

This invention is a(n): process chemical compound x therapeutic method
electronic circuit mixture of chemical compounds apparatus
other

The problem which this invention solves is:

The significance of this invention lies in its applicability in large variety of painful condition in human. Thus, the analgesic efficacy of topically applied local anesthetics and opioids may be dramatically improved by the addition of clonidine or agmatine. Many of the side-effects of local anesthetics and opioids, such as respiratory depression, constipation, cardio- and neurotoxicity, could be avoided by delivering a drug directly to the site of the pain without significant systemic absorption.

The closest prior art is: (* Please attach copies of relevant publications.)**g) This invention differs from the closest prior art in that:**

It provides a topical approach, which may limit systemic toxicities and side effects

h) This invention provides the following advantages:

i) This invention possesses the following disadvantages or limitations (describe how they can be overcome if applicable).

j) Has the invention or any project derived therefrom been:

1. Described in a printed publication. NO _____ Date _____
2. Described in an oral presentation. NO _____ Date _____
3. Sold, offered for sale, or used in public? NO _____ Date _____
4. Are any of 1 through 3 contemplated in the near future and, if so, when?

(If the answer to any of 1 through 4 is YES, provide detailed information, including copies of manuscripts, published articles, abstracts, etc., together with a floppy disk containing the text of any of your manuscripts, papers or abstracts, etc. that describe the invention. Please indicate the word processing software, version and system [e.g., Wordperfect 5.1, 6.1, 7.0 or MSWord 7.0; RTF; or TXT; IBM].)

3) NCI Core Grant No. 08748. Other Grant(s)/Contract(s) (VERY IMPORTANT IF APPLICABLE):

Sponsor NIH Award No. DA00405-01

Principal Investigator: Dr. Yuri Kolesnikov

4) Lab/Department where developed:

Laboratory of Molecular Neuropharmacology

01/19/02 FRI 10:43 FAX 212 211 3439



M S R C C

Contractual Agreements with Other Parties (include name of person contacted and copies of pertinent agreements):

6) Who contributed to the invention or discovery? Please identify all colleagues who could merit co-authorship credit for the associated publication:

Name <u>Dr. Gavril W. Pasternak</u>	Ext. <u>7046</u>
Home Address: <u>500 E 23 St, NY NY 10028</u>	Dept. <u>1905</u>
	Phone No. (<u>212</u>) <u>288-3257</u>
	Citizenship <u>USA</u>
Name <u>Yuri Kolesnikov</u>	Ext. <u>2846</u>
Home Address: <u>38 Ridge Rd.</u>	Dept. <u>Anesthesiology</u>
<u>Cresskill, NJ, 07626</u>	Phone No. (<u>201</u>) <u>871-7797</u>
	Citizenship: <u>Russia (Green Card)</u>
Name _____	Ext. _____
Home Address _____	Dept. _____
	Phone No. (_____) _____
	Citizenship _____
Name _____	Ext. _____
Home Address _____	Dept. _____
	Phone No. (_____) _____
	Citizenship _____
Name _____	Ext. _____
Home Address _____	Dept. _____
	Phone No. (_____) _____
	Citizenship _____

(Include additional names along with the above information on a separate sheet.)

SIGNATURE OF INVENTOR(S):	SIGNATURES OF WITNESS(ES):
	
I _____	
Da _____	
Date _____, 19____	Date _____, 19____

PATENT
830010-2002.2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Pasternak et al.
Serial No. : 09/975,812
For : TOPICAL ANESTHETIC/OPIOID
FORMULATIONS AND USES THEREOF
Filed : October 11, 2001
Examiner : Bahar
Art Unit : 1617

745 Fifth Avenue
New York, NY 10151

EXPRESS MAIL

Mailing Label Number: EV 196819225 US

Date of Deposit: June 25, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Charles B. Jackson

(Typed or printed name of person mailing paper or fee)


(Signature of person mailing paper or fee)

DECLARATION OF DR. SANDRA C. ROERIG UNDER 37 C.F.R. § 1.132

I declare as follows:

1. I am an associate editor of the editorial board of the Journal of Pharmacology and Experimental Therapeutics. I am familiar with U.S. Application Serial No. 09/975,812. I have been informed that U.S. Application Serial No. 09/975,812 was filed on October 11, 2001, claiming priority to 09/844,111, filed on April 27, 2001 and U.S. Provisional Application Serial No. 60/200,437, filed April 28, 2000. My curriculum vite is provided under Tab 1. I respectfully submit that I am qualified to speak and render opinions as to the

PATENT
830010-2002.2

disclosure in the present application, the state of the art and the procedures of editorial review at the Journal of Pharmacology and Experimental Therapeutics. Furthermore, I have reviewed the experimental work discussed herein, in the ordinary course of business.

2. I am familiar with the Office Action dated February 26, 2003, issued by the United States Patent and Trademark Office in connection with the present application and make this Declaration in response thereto. I will address the following issue to respond to the Examiner's rejections:

The role of peripheral mechanisms in the mediation of antinociceptive responses was unknown prior to the teaching of the present invention. Opioid analgesia was thought to be mediated through the central nervous system (i.e. systemically) rather than through peripheral opioid receptors. Those skilled in the art did not appreciate the significance of peripheral opioid receptor stimulation, much less the significance of combining opioid analgesics and local anesthetics at these peripheral sites. The synergistic potentiation of pain relief that occurs at peripheral sites when opioid analgesics are administered together with local anesthetics was unexpected, especially given that only small amounts of each drug are needed to produce a synergistic response.

3. Details of the editorial review process are described herein. The Journal of Pharmacology and Experimental Therapeutics invites for review original papers dealing with interactions of chemicals with biological systems. All aspects of pharmacology and therapeutics are appropriate. The American Society for Pharmacology and Experimental Therapeutics, which the journal is a member of, requires authors to affirm that original studies reported in the journals of the Society have been carried out in accordance with the Declaration of Helsinki and/or with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health.
4. At least two independent reviewers, skilled in the art, are selected for each submitted manuscript. The review is blinded such that the two selected reviewers are unaware of each

PATENT
830010-2002.2

other. Comments to the author are intended to be constructive without indicating acceptability of the manuscript. Based substantially on the reviewers' comments, the Associate Editor makes a decision to accept or deny the manuscript for publication. A copy of the reviewers' comments for authors Drs. Yuri Kolesnikov, Igor Chershev, and Gavril W. Pasternak in response to the manuscript entitled "Analgesic Synergy between Topical Lidocaine and Topical Opioids", is provided under Tab 2. A copy of the manuscript in its published form is provided under Tab 3. To the best of my knowledge, the data reviewed and described in the publication is the same as in the present application.

5. The present invention is directed to topical administration of morphine and lidocaine, which together produce a synergistic antinociceptive response in the periphery. The position of our reviewers was that the synergistic effect of topical morphine and lidocaine at the amounts used was "profound" and "quite marked." Essentially, their position was that the result was unexpected. In addition, one of the reviewers noted that studies of this kind had "never been performed previously." These statements, dated May 19, 2000, provide evidence of the state of the art, from those skilled in the art, at the time the instant application was filed.
6. I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Dated 5/12/03By: Sandra C. Roerig
Sandra C. Roerig

TAB - 1

CURRICULUM VITAE

**Sandra C. Roerig
Department of Pharmacology
Louisiana State University
Health Sciences Center
1501 Kings Highway
Shreveport, LA 71103-3932**

**phone (318) 675-7877
fax (318) 675-7857
sroeri@lsuhsc.edu**

EDUCATION

B.S., Horticulture, Kansas State University, 1967

M.S., Pharmacology, Medical College of Wisconsin, 1976

Ph.D., Pharmacology, Medical College of Wisconsin, 1988

EXPERIENCE

2001-present	Associate Dean for Research and Graduate Studies Louisiana State University Health Sciences Shreveport, LA
July 2002-present	Professor, Department of Pharmacology and Therapeutics Louisiana State University Health Sciences Center Shreveport, LA
July 2002-present	Professor, Department of Anesthesiology Louisiana State University Health Sciences Center Shreveport, LA
2000-2001	Assistant Dean, School of Graduate Studies Louisiana State University Health Sciences Shreveport, LA
1997-2002	Associate Professor, Department of Pharmacology and Therapeutics Louisiana State University Health Sciences Center Shreveport, LA
1991 - 1997	Assistant Professor, Department of Pharmacology and Therapeutics Louisiana State University Medical Center Shreveport, LA
1989-1991	Postdoctoral Fellow, Department of Pharmacology University of Minnesota, Minneapolis, MN Advisor: Dr. Horace H. Loh

- 1988 -1989 Postdoctoral Fellow, Department of Pharmacology
University of Minnesota, Minneapolis, MN
Advisor: Dr. George L. Wilcox
- 1984 - 1987 Graduate Student, Department of Pharmacology and Toxicology
Medical College of Wisconsin, Milwaukee, WI
Advisor: Dr. James M. Fujimoto
- 1976-1984 Research Associate, Department of Pharmacology and Toxicology
Medical College of Wisconsin, Milwaukee, WI
Supervisor: Dr. James M. Fujimoto
- 1975-1976 Graduate Student, Department of Pharmacology and Toxicology
Medical College of Wisconsin, Milwaukee, WI
Advisor: Dr. James M. Fujimoto
- 1972-1975 Research Technician, Department of Pharmacology
Medical College of Wisconsin, Milwaukee, WI
Supervisor: Dr. James M. Fujimoto
- 1969-1971 Research Technician, Biochemistry, AEC Plant Research Lab
Michigan State University, East Lansing, MI
Supervisor: Dr. Derek T.A. Lamport
- 1967-1969 Research Technician, Department of Biochemistry
University of Kansas Medical Center, Kansas City, KS
Supervisor: Dr. Dennis Diedrich, Dr. Santiago Grisolia
- 1965-1967 Research Technician, Horticulture, School of Agriculture
Kansas State University, Manhattan, KS
Supervisor: Dr. William Carpenter

SOCIETY MEMBERSHIPS

American Society for Pharmacology and Experimental Therapeutics
American Society for the Advancement of Science
Society for Neuroscience
American College of Clinical Pharmacology (Fellow)
International Narcotics Research Council

AWARDS

Tuition Scholarship, Medical College of Wisconsin, Graduate Studies Council, (1985-1986)
Travel Award, American Society for Pharmacology and Experimental Therapeutics, (1986)
Travel Award, Friends of Medical College of Wisconsin (1987)
Travel Award, Committee on Problems of Drug Dependence (1988)
Travel Award, American College of Neuropsychopharmacology (1988)

TEACHING

Student Conferences, General Pharmacology, Medical College of Wisconsin (1984-1987)

Lectures, General Pharmacology, School of Nursing, Medical College of Wisconsin (1984)

Teaching Assistant, Neuroscience Summer Workshop, Lake Itasca, University of Minnesota, (1988)

Medical Pharmacology Lectures and Student Conferences,
LSU Health Sciences Center (1991-present)

Clinical Pharmacology Conferences,
LSU Health Sciences Center (1992 - 1999)

Lectures in Graduate level courses:

Principles of Pharmacology I and II, Neurochemistry, Philosophical and Ethical Issues in Science,
Behavioral Pharmacology, Neuropharmacology, Molecular Pharmacology, Integrative Structural
Biology, Fundamentals of Biological Sciences
LSU Health Sciences Center (1992- present)

Course Director:

Principles of Pharmacology I, (1993-1996) Molecular Pharmacology (1996-2000) Clinical
Pharmacology Conferences (1993 - 1998), LSU Health Sciences Center

Joint LSUHSC Physiology Department-Centenary College Summer Seminar Series
Lectures in Mentoring to undergraduate students (1996-present)

GRADUATE EDUCATION

Postdoctoral Fellows

Natalie Lenard, Ph.D., 2003-present

Guoqiang Guan, D.D.S., Ph.D., 2000-2002

Department of Pharmacology LSU Health Sciences Center Graduate Students

Research Advisor for: Zhong You Wei, Yaohui Li, Farzana Karim, Laura Tedesco, Scott Baker

Dissertation/Thesis committee member for: Ying Ye, Kehong Zhang, Pankaj Sikka, Donna Ross,
James Hinson, Orlando Bueno, Alicia Chrisman, Yu Zhao, Troy Cenac, Olga Gurkovskaya,
Rachell Romanoff

Students Graduated:

Zhong You Wei, M.S., 1995

Thesis title: Voltage-dependent calcium channels and G proteins in spinal morphine/clonidine
synergistic antinociception

Yauhui Li, M.S., 1997

Thesis title: Alterations of Spinal Protein Kinase C Expression and Kinetics in Morphine Tolerance

Farzana Karim, Ph.D. 1999

Dissertation title: Functional aspects of opioid and α_2 adrenergic receptor activation: involvement of specific G proteins

Medical Student Summer Research Program

Students mentored:

Jeb Broyles (1993)
Eric Madore (1994)
Matthew Chamberlain (1996)
Joan Cheuk (1999)

Undergraduate and Teacher Summer Research Program

Students Mentored:

Lisa Walker (1994)
Chancy Burden (1998)
Kavita Belur (1997)

Multicultural Affairs "Jump-Start Program" for High School Students

Students Mentored:

Deana Rambo (summer 2000)

Other Student-Related Activities

Department of Pharmacology and Therapeutics Graduate Student Coordinator (1997-2000)

Organized LSUHSC-Shreveport Graduate Student Orientation (2000)

GRANT SUPPORT

Awarded as Principle Investigator

National Institute on Drug Abuse, Research Fellowship Award DA 05370 (Oct. 1, 1988-Sept. 30, 1991) - "Partial Characterization of Cloned Delta Opioid Receptor"

The Edward P.S. Stiles Trust Fund - LSUMC-S Institutional Funds, Young Investigator Award (Nov. 1, 1991 - Oct. 31, 1992) "Spinal Opioid and Adrenergic Analgesia in Opioid Tolerance" - \$7,450. Renewed (Dec. 1, 1992 - Nov. 30, 1993) - \$7,462

American Cancer Society Junior Investigator Award, Institutional support (May 1, 1992-June 30, 1993) "Identification of GTP-binding proteins which transduce spinal opioid receptor functions" - \$6,000

Louisiana Education Quality Support Fund (July 1, 1993 - June 30, 1996) "Second messenger systems involved in opioid and alpha adrenergic interactions" - \$144,976 - Approved

National Institutes on Drug Abuse, FIRST Award (May 1, 1993 -April 30, 1998) "Opioid and Alpha Adrenergic Agonist Interactions" - DA07972-\$350,018

The Edward P.S. Stiles Trust Fund - LSUMC-S Institutional Funds, Bridging Award, "Opioid and Alpha Adrenergic Agonist Interactions" (January 1, 1999-December 30, 1999, \$30,000)

National Institutes on Drug Abuse, RO3, DA12547, "Spinal nitric oxide in chronic inflammatory pain" (1/1/00-12/31/01) \$100,000

Awarded as Contract for Program Project

National Institutes on Drug Abuse, Program Project, "Design of opioid analgesics devoid of tolerance/addiction", PI, Ping Law, University of Minnesota (6/1/02-5/30/07) \$340,926

Awarded as Co-Investigator

National Institutes of Child Health and Development, RFA 9306, Pediatric Drug Evaluation Resource (9/30/93-9/30/98) Principle Investigator, John Wilson, M.D., Efficacy and pharmacokinetics of tramadol for treatment of pain in children, Sandra C. Roerig, Basic Investigator - \$1,600,000

Submitted, October 1, 2001

National Institutes on Drug Abuse RO1 - "Spinal nitric oxide in chronic inflammatory pain" for 7/1/02-6/30/06, \$500,000, not funded, will be resubmitted

SERVICE

GRANT REVIEWER

National Grant Reviews:

Study Sections:

ad hoc reviewer for SBIR applications, Molecular Biology Section - July 1998

ad hoc reviewer for IFCN-4, National Institutes of Health, October 14-16, 1998

ad hoc reviewer for NIH IFCN-7, SBIR Study section - April 2000, August 2001, March 2002, April 2003

Phone Reviews:

ad hoc reviewer for NIH (Tallarida) - October 1993

ad hoc reviewer for intramural grant at Allegany College, PA , 1997

ad hoc reviewer for EPSCoR grant application, March 1998

ad hoc reviewer for NIH IFCN-4, December 1998

Special Grant Reviewer for NIH, October 1995, December 1998, March 1999

ad hoc reviewer and chair of IFCN5-03 Study Section - October 2000

ad hoc reviewer for IFCN2 - December 2001

LSUHSC COMMITTEE SERVICE

1. Department of Pharmacology

1992, 1994, 2000	Pharmacology Faculty Search Committee	Member
1993, 1996, 2000	Qualifying Exam Committee	Member
1994	Faculty review of USMLE Step 1 (Nov. 17, 1993)	Member

2. LSUHSC - Shreveport

1994	Search Committee for Head, Dept. of Neurology	Member
1993-1997	Radiation Safety Committee	Member
1998- 2001	Ratiation Safety Committee	Chair
1997-1999, present	Admissions Committee	Member
1996	Reviewer of Cancer Center Applications	Member
1995-1998	Elected Faculty Council	Member
1997-1998	Elected Faculty Council	Chair
1995-1997, 2000	Research Advisory Committee	Member
1997-1999	Radioactive Drug Research Committee	Member
1998-1999	LCME Visit Preparation Committee	Member
1999	Clinical Research Committee	Member
1999-present	Committee on Committees	Member
1999-present	Curriculum Committee	Member
2000-present	Committee to Draft Faculty Senate Bylaws	Member

3. LSUHSC - Faculty Senate for both campuses, Shreveport and New Orleans

1997-2001	LSUHSC - Shreveport Graduate School Representative	Member
1997-2001	Subcommittee for Faculty Welfare	Member
1999-2001	Representative to the Board of Supervisors	
2000-2001		Chair-elect

NATIONAL COMMITTEES

American Society for Pharmacology and Experimental Therapeutics
 Subcommittee for Women in Pharmacology (1994-present)
 Committee for Division of Education (2000-present)

Steering committee for 4th International Symposium on Imidazoline/Agmatine Systems
 2001 - present

OTHER SERVICE

Director, Department of Pharmacology Seminar Program: LSU Medical Center (1993-1995)

Assistant Dean, School of Graduate Studies, LSUHSC-Shreveport, October 2000 - present

INVITED SEMINARS**Louisiana State University****1. Medical Center in Shreveport campus**

Department of Cell Biology and Anatomy - 1992

Pathophysiology of Pain Symposium - 1993

Department of Neurology Grand Rounds - 1995

Clinical Pharmacology Interest Group -1996

Department of Molecular and Cellular Physiology -1998

2. Shreveport campus (undergraduate)

Seminars for the Department of Biology (1992-1996, 1999, 2001)

National

Department of Pharmacology, University of Texas Medical Center, Houston, TX (1993)

Department of Physiology, University of North Texas Health Sciences Center, Fort Worth, TX (1993)

Department of Pharmacology, University of Wisconsin - Madison, Madison, WI (1994)

Department of Pharmacology, Michigan State University, East Lansing, MI (1997)

Department of Pharmacology, University of Houston School of Pharmacy - Houston, TX (2000)

Department of Pharmacology, University of Arkansas Medical School - Little Rock, AR (2000)

OTHER PRESENTATIONS

June 7, 1997, Role of Protein Kinases in Spinal Morphine/Clonidine Antinociceptive Synergism, Pain Interest Group Meeting, Milwaukee, WI

CONTRIBUTIONS TO REFERRED PUBLICATIONS

- 1999 - present - Associate Editor, *Journal for Pharmacology and Experimental Therapeutics*
- 1994-1998 - Editorial Advisory Board, *Journal for Pharmacology and Experimental Therapeutics*
- 1995 - present - Editorial Board, *Analgesia*
- 1990-present - reviewer for *Brain Research*, *Journal of Neurochemistry*, *Life Sciences*, *Brain Research Bulletin*, *Peptides*, *Proceedings of the Society for Experimental Biology and Medicine*, *Journal for Pharmacology and Experimental Therapeutics*, *Journal for Neuroscience*, *Pain*, *Free Radical Biology and Medicine*, *Neurochemistry International*

PUBLICATIONS

- Roerig, S., Fujimoto, J.M., Wang, R.I.H., Isolation of hydromorphone and dihydromorphone glucuronides from urine of the rabbit after hydromorphone administration. *Proc. Soc. Expt. Biol. Med.* 143: 230-233 (1973)
- Chatterjie, N., Fujimoto, J.M., Inturrisi, C.E., Roerig, S., Wang, R.I.H., Bowen, D., Field, F.H., and Clarke, D.D., Isolation and stereochemical identification of a metabolite of naltrexone from human urine. *Drug Metab. Disp.* 2: 401-405 (1974)
- Fujimoto, J.M., Roerig, S., Wang, R.I.H., Chatterjie, N. and Inturrisi, C.E., Narcotic antagonist activity of several metabolites of naloxone and naltrexone tested in morphine dependent mice. *Proc. Soc. Expt. Biol. Med.*, 148: 443-448 (1975)
- Lamport, D.T.A., Katona, L. and Roerig, S., Galactosylserine in extensin. *Biochem. J.*, 133: 125 (1976)
- Roerig, S., Fujimoto, J.M., Wang, R.I.H., and Lange, D.G., Preliminary characterization of enzymes for reduction of naloxone and naltrexone in rabbit and chicken liver. *Drug Metab. Disp.* 4: 53-58 (1976)
- Roerig, S.C., Fujimoto, J.M., and Wang, R.I.H., The stimulatory effect of morphine on metabolism of naloxone to 6 α -naloxol in the guinea pig. *Drug Metab. Disp.* 5: 454-463 (1977)
- Roerig, S.C., Fujimoto, J.M. and Wang, R.I.H., The stimulatory effect of morphine on reduction of naltrexone to 6 α -naltrexol in the guinea pig. *Drug Metab. Disp.* 8:295-299 (1980)
- Roerig, S.C., Christiansen, K.L., Jansen, M.A., Wang, R.I.H., Fujimoto, J.M., and Nickerson, M., Phylogenetic distribution of the hepatic enzyme system for reducing naloxone to 6 α - and 6 β -naloxol in vertebrates. *Comp. Biochem. Physiol.* 15: 93-97 (1980)
- Lange, D.G., Roerig, S.C., Fujimoto, J.M. and Wang, R.I.H., Absence of cross-tolerance to heroin in morphine tolerant mice. *Science* 208: 72-74 (1980)
- Lange, D.G., Roerig, S.C., Fujimoto, J.M. and Wang, R.I.H., Enhancement of etorphine brain concentrations and changes in etorphine-naloxone pA₂ values in morphine pretreated mice. *Biochem. Pharm.* 30: 147-155 (1981)

Lange, D.G., Roerig, S.C., Fujimoto, J.M. and Busse, L.W., Withdrawal tolerance and unidirectional non-cross tolerance in narcotic pellet implanted mice. *J. Pharmacol. Exp. Ther.*, 224: 13-20 (1983)

Brown, C.E., Roerig, S.C., Fujimoto, J.M. and Burger, V.T., The structure of morphine differs between the crystalline state and aqueous solution. *J. Chem. Soc., Chem Commun.* 1506-1508 (1983)

Roerig, S.C., O'Brien, S.M., Fujimoto, J.M. and Wilcox, G.L., Tolerance to morphine analgesia: decreased multiplicative interaction between spinal and supraspinal sites. *Brain Res.* 308: 360-363 (1984)

Brown, C.E., Roerig, S.C., Burger, V.T., Cody, R.B. and Fujimoto, J.M., Analgesic potencies of morphine 3- and 6-sulfates after intracerebroventricular administration in mice: relationship to structural characteristics defined by mass spectrometry and nuclear magnetic resonance, *J. Pharm. Sci.*, 74: 821-824 (1984)

Roerig, S.C., Fujimoto, J.M., Franklin, R.B. and Lange, D.G., Unidirectional non-cross tolerance (UNCT) in rats and an apparent dissociation between narcotic tolerance and physical dependence. *Brain Res.* 327: 91-96 (1985)

Roerig, S.C., Fujimoto, J.M. and Lange, D.G., Development of tolerance to respiratory depression in morphine- and etorphine-pellet-implanted mice. *Brain Res.*, 400: 278-284 (1987)

Roerig, S.C., Arteau, C. and Fujimoto, J.M., Antagonism by nalmefene of systemic and intrathecal morphine-induced analgesia in mice. *Proc. Soc. Expt. Biol. Med.*, 186: 234-239 (1987)

Roerig, S.C., Fujimoto, J.M. and Tseng, L.F., Comparisons of descending pain inhibitory pathways activated by β -endorphin and morphine as characterized by supraspinal and spinal analgesic interactions in mice. *J. Pharmacol. Exp. Ther.* 247: 1107-1113 (1988)

Roerig, S.C. and Fujimoto, J.M., Morphine analgesia in different strains of mice: relationship of supraspinal-spinal multiplicative interaction to tolerance. *J. Pharmacol. Exp. Ther.*, 247: 603-608 (1988)

Roerig, S.C. and Fujimoto, J.M., Multiplicative interaction between intracerebroventricularly and intrathecally administered morphine for analgesia in mice: involvement of mu, delta and kappa receptors. *J. Pharmacol. Exp. Ther.* 249: 762-768 (1989)

Rady, Jodie J., Roerig, Sandra C. and Fujimoto, James M., Heroin acts on different opioid receptors than morphine in Swiss Webster and ICR mice to produce antinociception, *J. Pharmacol. Exp. Ther.* 256: 448-457 (1991)

Roerig, S.C., Hoffman, R.G., Takemori, A.E., and Fujimoto, J.M., Isobolographic analyses of analgesic interactions between intracerebroventricularly and intrathecally administered opioid agonists: morphine, fentanyl and D-Ala²-D-Leu⁵-enkephalin. *J. Pharmacol. Exp. Ther.*, 257: 1091-1099 (1991)

Roerig, Sandra C., Loh, H.H. and Law, P.Y., Requirement of ADP-ribosylation for the pertussis toxin-induced alteration in electrophoretic mobility of G-proteins. *Biochem. Biophys. Res. Comm.*, 180:1227-1232 (1991)

- Roerig, S.C., Lei, S., Kitto, K., Hylden, J.K.L. and Wilcox, G. L., Interactions between spinally administered opioid and noradrenergic agonists in the substance P test in mice: multiplicity involves δ and α_2 receptors. *J. Pharmacol Exp. Ther.*, **262**: 365-374 (1992)
- Roerig, Sandra C., Law, P.Y. and Loh, H.H., Identification of three separate guanine nucleotide-binding proteins which interact with the δ opioid receptor in NG108-15 neuroblastoma x glioma hybrid cells. *Mol. Pharm.*, **41**: 822-831 (1992)
- Dujic, Z., Marijic, J., Roerig, S. C., Dujic, J., Kampine, J. P. and Bosnijak, Z., Presynaptic modulation of acetylcholine release from the cat stellate ganglion by morphine, *Croatian Med. J.*, **34**: 33-42 (1993)
- Saphier, D., Roerig, S.C., Ito, C., Vlasak, W.R., Farrar, G.E., Broyles, J.E. and Welch, J.E., Inhibition of neural and neuroendocrine activity by α -interferon: neuroendocrine, electrophysiological and biochemical studies in the rat, *Brain, Behav Immun.*, **8**:37-56 (1994)
- Roerig, Sandra C. , Decreased spinal morphine/clonidine antinociceptive synergism in morphine-tolerant mice, *Life Sci*, **56**: PL115-PL122 (1995)
- Roerig, Sandra C., Cynthia L. Williams, Victor J. Hruby, Thomas F. Burks and Gary Rosenfeld, Inhibition of adenylyl cyclase activity by the cholecystokinin analog SNF9007 in neuroblastoma x glioma NG108-15 hybrid cells, *Reg. Peptides*, **61**: 51-56 (1996)
- Wei, Zhong you, Farzana Karim and Sandra C. Roerig, Spinal morphine/clonidine antinociceptive synergism: involvement of G proteins and N-type voltage-dependent calcium channels, *J. Pharm. Exp. Therap.* **278**:1392-1407 (1996)
- Roerig, Sandra C. and Kurt Howse, ω -Agatoxin IVA blocks spinal morphine/clonidine antinociceptive synergism, *Eur. J. Pharmacol.* **314**:293-300 (1996)
- Wei, Zhong you and Sandra C. Roerig, Spinal morphine/clonidine antinociceptive synergism is regulated by protein kinase C, but not protein kinase A activity, *J. Pharmacol. Exp. Therap.* **287**:937-943 (1998)
- Li, Yaohui and Sandra C. Roerig, Alteration of Spinal Protein Kinase C Expression and Kinetics in Morphine, but not Clonidine Tolerance, *Biochem Pharmacol.*, **58**:493-501 (1999)
- Roerig, Sandra C., Timothy Busch and Yaohui Li, Decreased spinal morphine/clonidine antinociceptive synergism in clonidine-tolerant mice, *Analgesia*, **4**:187-195 (1999)
- Napier, Leslie D., Sandra C. Roerig, Darice A. Yoshishige, Barbara A. Barron and James L. Caffrey, Canine cardiac muscarinic receptors, G-proteins and adenylate cyclase following chronic morphine, *J. Pharmacol. Exp. Ther.*, **291**: 725-732 (1999)
- Zavec, James, H., Harold D. Battarbee, Orlando Bueno, Ronald E. Maloney, Sandra C. Roerig and James M. O'Donnell, Down regulation of cardiac L-type Ca^{2+} channels in the portal hypertensive rat *Amer. J. Physiol.*, **279**:G28-G39 (2000)
- Karim, Farzana and Sandra C. Roerig, Differential effects of antisense oligodeoxynucleotides directed against $\text{G}_{\text{Z}\alpha}$ and $\text{G}_{\text{O}\alpha}$ on antinociception produced by spinal opioid and α_2 adrenergic receptor agonists (*Pain*, **87** 181-191, 2000)

Tedesco, Laura, John Fuseler, Matther Grisham, Robert Wolf and Sandra C. Roerig, Nitric oxide synthase inhibitors reverse hyperalgesia but not inflammation in a rat model of chronic arthritis *Pain*, 95: 215-223, 2002

Roerig, Sandra C., Spinal and supraspinal agmatine activate different receptors to enhance spinal morphine antinociception (submitted, *J. Pharmacol. Exp. Ther.*)

Karim, Farzana, Paul Prather and Sandra C. Roerig, Opioid and α_2 -adrenergic receptor agonists enhance incorporation of [α - 32 P] GTP azidoanilide into spinal G proteins (submitted, *Biochem. Pharm.*)

ABSTRACTS

Lamport, D.T.A., Katona, L. and Roerig, S., Amino acid sequence of hydroxyproline-rich tryptic peptides from acid-stripped primary cell walls. *Fed. Proc.* 30: 1317 (1971)

Lange, D.G., Fujimoto, J.M., Roerig, S.C. and Wang R.I.H., Morphine induced sensitization to naloxone: enhanced disposition of naloxone to the brain. *The Pharmacologist*, 16: (1974)

Lange, D.G., Fujimoto, J.M., Roerig, S. and Wang, R.I.H., The Effect of morphine on the metabolism of naloxone. National Drug Abuse Conference (1976)

Fujimoto, J.M., Roerig, S.C. and Wang, R.I.H., Reduction of naloxone by the guinea pig. *Fed. Proc.* 34: 487 (1976)

Roerig, S., Fujimoto, J.M., Nickerson, M. and Wang, R.I.H., A preliminary comparison of the liver enzyme systems for reducing naloxone to 6 α - and 6 β -naloxol. Abstracts of Papers, Soc. of Toxicol., 15th Annual Meeting, 87 (1976)

Roerig, S., Fujimoto, J.M. and Wang, R.I.H., Stimulation of morphine on metabolism of naloxone to 6 α -naloxol in the guinea pig. *The Pharmacologist*, 18: 121 (1976)

Roerig, S.C., Fujimoto, J.M. and Wang, R.I.H., Effect of morphine on naltrexone metabolism in the guinea pig. *The Pharmacologist*, 20: 546 (1978)

Fujimoto, J.M., Lange, D.G., Roerig, S.C. and Wang, R.I.H., Development of differential tolerance to narcotic agonists by etorphine pellet implantation in mice. *The Pharmacologist*, 21: 79 (1979)

Roerig, S.C., Fujimoto, J.M. and Lange, D.G., Separation of expression of narcotic tolerance from physical dependence in rats. *The Pharmacologist*, 21:439 (1976)

Lange, D.G., Fujimoto, J.M., and Roerig, S.C., Continuous intraventricular infusions of narcotic agonists does not alter analgesic potency of systemically administered narcotics. *The Pharmacologist*, 21: 440 (1976)

Roerig, S.C., Lange, D.G., Wang, R.I.H., and Fujimoto, J.M., Differences in withdrawal tolerance ED₅₀ values for several narcotics in etorphine pelleted mice. *The Pharmacologist*, 22: 786 (1980)

Roerig, S.C., Lange, D.G., and Fujimoto, J.M., Comparison of tolerance to respiratory depression from morphine (M), etorphine (E) and heroin (H) in morphine pellet implanted mice. *The Pharmacologist*, 23: 115 (1981)

Roerig, S.C., Lange, D.G. and Fujimoto, J.M., Tolerance to the potent narcotic analgesic morphine-6-etheral sulfate (M6ES) in mice. *The Pharmacologist*, 24: 126 (1982)

Roerig, S.C., Lange, D.G., and Fujimoto, J.M., Tolerance development in morphine pellet implanted mice to intrathecally administered delta but not mu receptor agonists. *Fed. Proc.* 43: 968 (1984)

Brown, C.E., Roerig, S.C., Fujimoto, J.M. and Burger, V.T. CP/MAS ¹³C NMR spectral evidence of long-range substituent effects in rigid opiates. *Fed. Proc.* 42(7): A2056 (1983) (Amer. Soc. Biol. Chemists)

Brown, C.E., Roerig, S.C., Fujimoto, J.M. and Burger, V.T. CP/MAS ¹³C NMR spectral evidence of long-range substituent effects in rigid opiates. International Magnetic Resonance meeting (Aug, 1983)

Roerig, S.C., O'Brien, S.M. and Fujimoto, J.M., Morphine analgesic tolerance: decreased synergistic interaction between spinal and supraspinal sites in morphine pellet (MP) implanted mice. *Fed. Proc.* 43(4): 968 (1984)

Roerig, S.C., O'Brien, S.M. and Fujimoto, J.M., Tolerance to morphine hot plate analgesia (HPA): decrease in synergism between spinal (S) and supraspinal (SS) sites. *The Pharmacologist*, 26: 14 (1984)

Roerig, S.C., O'Brien, S.M. and Fujimoto, J.M., Basis for lack of analgesic cross tolerance to heroin (H) in morphine (M) tolerant mice. IUPHAR 9th International Congress of Pharmacology, 1549P (1984)

Roerig, S.C. and Fujimoto, J.M., Analgesic synergism between intracerebroventricular (ICV) and intrathecal morphine sulfate remains unaltered after ICV 6-hydroxydopamine. *Fed. Proc.* 44(5): 1721 (1985)

Roerig, S.C., Majest, S.M. and Fujimoto, J.M., Differential sensitivity to naloxone HCl (N) between spinal and supraspinal sites in mice. *The Pharmacologist*, 27: 117 (1985)

Brown, C.E., Roerig, S.C., Burger, V.T., Cody, R.B. and Fujimoto, J.M., Analgesic potencies of morphine 3- and 6-sulfates after intracerebroventricular administration in mice: relationship to structural characteristics defined by laser desorption/fourier transform mass spectrometry and nuclear magnetic resonance. *The Pharmacologist*, 27: 275 (1985)

Roerig, S.C. and Fujimoto, J.M., Intrathecal 6-hydroxydopamine (6-OHDA) treatment decreases morphine analgesic synergism between spinal and supraspinal sites in mice. *Fed. Proc.* 45: 666 (1986)

Fujimoto, J.M., Roerig, S.C., and Arteau, C., Narcotic antagonist activity of nalmefene on peripheral and spinal morphine analgesia. *Fed. Proc.* 45: 667 (1986)

Roerig, S.C., Arteau, C. and Fujimoto, J.M., Spinal delta and kappa but not mu opiate receptors involved in spinal-supraspinal morphine synergism. *The Pharmacologist*, 28: 96 (1986)

Roerig, S.C., Fons, M.L. and Fujimoto, J.M., Tolerance to morphine by decreased synergism between intracerebroventricular (ICV) and intrathecal (IT) sites requires large degree of subcutaneous (SC) tolerance. *Fed. Proc.* 46: 389 (1987)

Roerig, S. C., Fujimoto, J.M. and Takemori, A. E., Isobolographic evaluation of synergistic vs. additive opioid interactions. *The Pharmacologist*, 29 : 10 (1987)

Roerig, S.C. and Fujimoto, J.M., Morphine sulfate (MS) stimulates different receptors supraspinally and spinally to produce an analgesic multiplicative interaction. *The FASEB Journal*, 2: A1393 (1988)

Fujimoto, J.M., Roerig, S.C., and Tseng, L.F., Separate analgesic (additive-multiplicative) pathways for morphine sulfate (MS) and β -endorphin. *The FASEB Journal*, 2: A1072 (1988)

Roerig, S.C., Kitto, K.F., Lei, S. and Wilcox, G.L., Multiplicative interaction between intrathecally applied opioids and cocaine involves δ receptors, *Soc. for Neurosci. Abst.* 14: 712 (1988)

Lei, S., Roerig, S.C. and Wilcox, G.L., Change in the multiplicative interaction of antinociceptive effects of intrathecal (i.t.) norepinephrine and morphine in morphine tolerant mice, *The Pharmacologist*, 30: A155 (1988)

Roerig, S.C., Kitto, K.F. and Wilcox, G.L., Change in morphine/clonidine interaction induced by opioid but not noradrenergic antagonist treatment, *The Pharmacologist*, 30: A155 (1988)

Roerig, S.C., Law, P.Y. and Loh, H.H., Interaction of delta opioid receptors with guanine nucleotide binding protein (G_i) after chronic opioid treatment. *The FASEB Journal*, 4:A1118 (1990)

Jodie J. Rady, Sandra C. Roerig and James M. Fujimoto, Heroin antinociception: opioid receptor mediation different from morphine. *The Pharmacologist*, 32: A183 (1990)

P.Y. Law, Sandra C. Roerig, Cynthia L. Lindholm, Sarah L. Sommer and Horace H. Loh, Opioid receptor activities in neuroblastoma x glioma NG108-15 cells followed prolonged exposure to forskolin and isobutylmethylxanthine (IBMX). *The Pharmacologist*, 32: A286 (1990)

Birnbaum, Angela K., Law, Ping Y., Roerig, Sandra and Wilcox, George L., Can voltage-clamped *Xenopus* oocytes detect receptor-driven alteration of cyclic AMP levels?, *Soc. for Neurosci. Abst.*, 16: 209 (1990)

Roerig, Sandra C. and Law, P.Y., Multiple $G_{i\alpha 3}$'s and $G_{o\alpha}$ s expressed in neuroblastoma x glioma NG108-15 hybrid cells. Amer. Soc. Cell Biology Meeting, 1990.

Roerig, Sandra C., Loh, Horace H. and Law, P.Y., Interaction of the delta opioid receptor with three different G-proteins in neuroblastoma x glioma NG108-15 cells, *The Pharmacologist*, 33:A34 (1991)

Sandra C. Roerig, Decreased spinal opioid α_2 interactions in morphine-tolerant mice. LSUMC Alcohol and Drug Abuse Retreat, October 2-3, 1992.

J.H. Zavec, H.D. Battarbee and S. Roerig, Cardiac β -adrenoceptor signal transduction is altered in the portal hypertensive rat, *The FASEB Journal*, 7(4) A778 (1993)

Sandra C. Roerig, Decreased spinal opioid/ α_2 interaction in morphine-tolerant mice, *The FASEB Journal* 7(4) A705 (1993)

Battarbee, H.D., Zavec, J.H., Roerig, S.C. and O'Donnell, J.M., Portal vein stenosis and cardiac impairment, American Gastroenterological Association meeting, May 1993.

Saphier, D. and Roerig, S.C., Central nervous system effects of α -interferon. 3 Research Perspectives in Psychoneuroimmunology IV, Boulder, CO, April 21-26, 1993

Saphier, D., Chuluyan, H.E. and Roerig, S.C., α -Interferon and μ -receptor mediated CNS effects. Seminar on "Substance Abuse and the Brain-Immune Axis." Satellite meeting of the College on Problems of Drug Abuse and Dependence, Toronto, Canada, June 17-18, 1993.

Roreig, Sandra C. and Henninger, Kellie, Effect of forskolin on antinociception produced by morphine and clonidine. LSUMC Alcohol and Drug Abuse Retreat, October 8-9, 1993.

Roerig, S.C., Williams, C.L., Hruby, V.J., Burks, T.F. and Rosenfeld, G.C., Cholecystokinin (CCK) analog SNF9007-induced inhibition of adenylyl cyclase activity in GN108-15 hybrid cells and SH-SY5Y cells shows differential activation of δ opioid receptors, *Regulatory Peptides*, 54:247 (1994)

Roerig, S.C., Williams, C.L., Hruby, V.J., Burks, T.F. and Rosenfeld, G.C., Cholecystokinin (CCK) analog SNF9007 activated δ opioid receptors to inhibit adenylyl cyclase activity in neuroblastoma x glioma NG108-15 cells, *Can. J. Physiol. Pharmacol.* 72 (Suppl. 1) 352 (1994)

Wei, Z.Y. and Roerig, S.C., Effects of intrathecal calcium channel agents on morphine/clonidine antinociceptive synergism. LSUMC Alcohol and Drug Abuse Retreat, October 28-29, 1994.

Howse, K.M. and Roerig, S.C., Effect of intrathecal pertussis toxin on morphine/clonidine antinociceptive synergism, LSUMC Alcohol and Drug Abuse Retreat, October 28-29, 1994.

Roerig, S.C. and Wei, Z.Y., Effect of ω -conotoxin on spinal morphine and clonidine antinociception, *The FASEB J.* 9 (3): A97 (1995)

Roerig, S.C., Wei, Z.Y. and Karim, F., N-Type calcium channels and pertussis toxin-sensitive G proteins are both required for spinal morphine/clonidine antinociceptive synergism, International Narcotics Research Conference, July, 1995.

Roerig, S.C. and K.M. Howse, Antinociceptive synergism between spinal morphine and clonidine is blocked by ω -agatoxin IVA, *The FASEB J.* 10(3):A 2604 (1996)

Li, Y., F. Karim, M. Chamberlain and S. Roerig, Change of protein kinase C kinetics in spinal cord of morphine-tolerant mice, LSUMC Alcohol and Drug Abuse Retreat, November 1-2, 1996.

Karim, F. and S. Roerig, Differential regulation of GTP binding proteins by chronic morphine and clonidine in the spinal cord, LSUMC Alcohol and Drug Abuse Retreat, November 1-2, 1996.

Roerig, S.C. and K.M. Howse, Both protein kinase A (PKA) and protein kinase C. (PCK) inhibitors block spinal morphine/clonidine antinociceptive synergism, International Narcotics Research Conference, July, 1996.

Li, Y., F. Karim, M. Chamberlain and S. C. Roerig, Change in spinal protein kinase C. (PCK) kinetics and expression in morphine-tolerant mice, *The Pharmacologist*, 39 (1) A 456 (1997)

Roerig, S.C. and T. Busch, Antinociceptive tolerance to clonidine without change in spinal morphine/clonidine synergism, *The Pharmacologist* 39 (1) A 466 (1997)

Karim F. and S.C. Roerig, Opioid and α_2 (α_2) adrenergic receptor agonist-enhanced incorporation of [32 P]GTP azidoanilide ([32 P]GTPAA) into GTP-binding proteins (G proteins) of mouse spinal neuronal membranes, Society for Neurosciences Abstracts, part 2, 1207 (1997)

F. Karim and S. Roerig, Differential effects of intrathecal G protein α subunit antisense on antinociception produced by morphine and clonidine, *FASEB J.* 12 (4) A156 (1998)

Roerig, Sandra C. and Farzana Karim, Spinal antisense oligodeoxynucleotide (ODN) to G α subunits blocks both morphine (MS) and clonidine (Cl) antinociception, International Narcotic Research Conference, July 1998.

Fuseler, J.W., S.C. Roerig, M.B. Grisham, V. Hall, D. Jourdain, S. Laroux, R.E. Wolf, Inhibition of inducible nitric oxide synthase exacerbates established joint inflammation and increases interleukin-6 levels in synovial tissue and serum, *Arthritis and Rheum.*, 41 (9) 1998

Roerig, S.C. and T. Busch, Intracerebroventricular (ICV) but not intrathecal (IT) agmatine enhances IT morphine (MS) antinociception through α_2 receptors, *FASEB J.*, 13 (5) A 801 (1999)

L. Tedesco, J. Fuseler, M. Grisham, R.E. Wolf and S. C. Roerig, Inhibition of nitric oxide synthase (NOS) activity reverses thermal hyperalgesia, but not mechanical allodynia or inflammation in peptidoglycan/polysaccharide (PG/PS)-induced polyarthritis. *FASEB J.*, 14 (8) A1317 (2000)

Sandra C. Roerig and Farzana Karim, Differential interactions between opioid and α_2 -adrenergic agonists for enhancing [32 P] GTP azidolanilide (GTP-AA) incorporation into spinal G α_{i1} , International Narcotics Research Conference, July 2000.

L. Tedesco, J. Fuseler, M. Grisham, R. Wolf and S. Roerig, Inhibition of nitric oxide synthase (NOS) activity reverses thermal hyperalgesia but not mechanical allodynia or inflammation in peptidoglycan/polysaccharide (PG/PS)-induced polyarthritis, Southeastern Pharmacology Society meeting, August, 2000.

Guoqiang Guan, Scott Baker, and Sandra C. Roerig, Inhibition of Spinal Nitric Oxide Synthase (NOS) Activity Reverses Carrageenan (CARRA)-induced Hyperalgesia But Not Inflammation In Rats, Experimental Biology, 2002

REVIEWS

Karim, Farzana, Sandra C. Roerig and David Saphier, Role of 5-hydroxytryptamine₃ (5-HT₃) antagonists in the prevention of emesis caused by anticancer therapy, *Biochem. Pharm.* 52:685-692 (1996)

Roerig, Sandra C., Opioid Regulation of Second Messenger Systems, *Analgesia* 3:231-250 (1998)

BOOK CHAPTER

Roerig, S.C., R. Wolf and M. Grisham, Nitric Oxide, Chronic Joint Inflammation and Pain, in *Nitric Oxide: Biology and Pathobiology*, 873-894 Ed. Louis Ignarro, Academic Press (2000)

OTHER PUBLICATIONS

Roerig, Sandra C. Comments on Tallarida and Miaskowski et al., *Pain* 51: 381-388 (1992)

Roerig, Sandra C., Drug Receptors and Signalling, in *Quick Look Pharmacology*, page 16-17, Ed. R.B. Raffa and G.H. Sterling, Fence Creek Publishing, Lyndell, PA (1999)

1 AB-2

JAN-24-2003 19:09 FROM: LAB MOLE, DR NEURO P 212-794-4332

11:512125880500

P: 4/4

The Journal of Pharmacology and Experimental Therapeutics

COMMENTS FOR AUTHOR

To Reviewer #1

Associate Editor: Sandra C. Roerig, Ph.D.

Manuscript (MS) #: JPET/2000/002825

MS Title: Analgesic Synergy between Topical Lidocaine and Topical Opioids

Authors: Yuri A. Kolesnikov, Igor Chershev, and Gavril W. Pasternak

INSTRUCTIONS FOR REVIEWER

1. When you have completed your review, please divide your comments into:
 - a) Comments for Editor - Please type directly onto the pink sheet.
These comments will not be sent to the author.
Comments regarding acceptability must be confined to the pink sheet.
 - b) Comments for Author - Please type directly onto this yellow sheet.
These comments should be constructive without indicating acceptability of the manuscript.

COMMENTS:

Date Reviewed: 5/19/00

The manuscript entitled "Analgesic synergy between topical lidocaine and topical opioids" (MS#002825) by Kolesnikov et al. describes the potential for further development of topical combination therapy for pain relief. The primary advantage of this treatment is the theoretical absence of side effects that can be problematic with most other forms of opioid administration. The synergistic effects were so profound, one wanted to know if the side effects really WERE absent under these conditions and whether tolerance would develop as rapidly to this drug combination as it might to the effect of a single drug. Obviously, those questions weren't asked in these studies, but it would be nice if there were some discussion of them in terms of practical uses for this approach. More specifically germane to the results from this study:

1. Did naloxone therapy have any effect on lidocaine analgesia alone?
2. Referring to Fig. 3A and its discussion in the text, was the naloxone administered in the same dose, by the same route and at the same time as was indicated in Fig. 5? This should be stated. More importantly, the authors state that the synergistic analgesic effect of lidocaine/morphine was significantly blocked by naloxone, but they don't say how much; the % of animals remaining analgesic after naloxone should be stated.
3. In fig. 5, lidocaine curves are included in both graphs and appear to be the same. At some point in this paper the authors should show the effects of naloxone alone in this paradigm. One spot would be to exclude lidocaine from one of these graphs and insert the naloxone curve instead.
4. On page 11 the authors state, "The activity of levorphanol and buprenorphine extends the activity of opioid systems beyond mu receptors." Are they referring to opioid systems active topically? They've already shown other opioid receptor subtype systems are active after peripheral and central administration. Additionally, while Levorphanol does elicit actions through non- μ opioid receptors, the results from these studies don't really address that point. The fact that a single dose of naloxone totally blocked lidocaine/Levorphanol analgesia suggests that Levorphanol was acting solely through μ receptors, since κ_2 analgesia is less sensitive to naloxone. In the absence of more selective μ antagonist treatments (e.g. β -FNA), the authors should avoid making such blanket statements.

Revised 4/27/00

JAN-24-2003 19:09 FROM: LAS MOLE R NEURO P 212-794-4332

10:512125880500

P12/4

Journal of Pharmacology and Experimental Therapeutics**Reviewer #2****Associate Editor: Dr. Roerig****MS #: JPET/2000/002825****MS Title: Analgesic synergy between topical lidocaine and topical opioids****Authors: Koesnikov, Chershnev and Pasternak**

This article is an extension of recently-completed studies performed by the authors examining the analgesic responses following topical administration of opioids in connection with other pharmacological agents. In this study, the authors perform straightforward and quite unambiguous demonstrations that topical lidocaine and topical opioids each produce analgesic responses alone, and display quite marked synergy following combined administration. It is very surprising given the advanced state of the field of analgesia that such studies have never been performed previously, but the authors conclusively demonstrate this important property of both drug classes. There are a number of comments and issues that should be addressed.

1. p. 3, line 8: "...lidocaine with a low dose of an opioid..."
2. p. 5: Topical administration: The authors should provide a 1-sentence rationale as to why a DMSO solution was used.
3. p. 8, results and Figure 1a: Indicate what dose of lidocaine was used in this particular initial experiment.
4. p. 9, lines 1 and 2: What dose and route of naloxone was used to reverse the analgesic effects of lidocaine and morphine?
5. p. 11, line 3: delete "an".
6. p. 11, line 10: "All of the opioids..."
7. p. 11, 1st sentence of third paragraph: The sentence does not make sense as presently constructed.
8. p. 12, line 11: "resulted from its receptor selectivity..."
9. p. 12, line 14: "...study. It will be of interest..."
10. The paper is devoid of any statistical data; it is up to the Editor if such additional data are necessary.

JAN-24-2003 19:09 FROMMER LAWRENCE & HAUG

PJ 2 US# 002825

Minor points:

1. Page 5, line 3 should read "housed" instead of "housing."
2. Page 12, line 12 - remove the word "get."
3. Page 12, line 14 - add the word "be". "It will be of interest..."
4. Fig. 5A legend, line 4 should read "application was tested in the tailflick assay."
5. Fig. 6A, Y-axis label misspelled.
6. Fixed ratios listed in Fig. 6 legend do not jive with fixed ratios given in Table 1 - which is correct? Also, Fig. 6A legend should be in reference to lidocaine/Levorphanol ratio, not buprenorphine.

TAB-3

0022-3656/00/2952-0546\$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics
JPET 295:546-551, 2000

Vol. 295, No. 2
2825/067034
Printed in U.S.A.

Analgesic Synergy between Topical Lidocaine and Topical Opioids¹

YURI A. KOLESNIKOV, IGOR CHERESHNEV, and GAVRIL W. PASTERNAK

The Departments of Anesthesiology (Y.A.K.) and Neurology (I.C., G.W.P.), Memorial Sloan-Kettering Cancer Center, New York, New York

Accepted for publication June 28, 2000 This paper is available online at <http://www.jpet.org>

ABSTRACT

Topical drugs avoid many of the problematic side effects of systemic agents. Immersion of the tail of a mouse into a solution of dimethyl sulfoxide (DMSO)-containing morphine produces a dose-dependent, naloxone-sensitive, analgesia (ED_{50} 6.1 mM; CL 4.3, 8.4) limited to the portion of the tail exposed to the drug. DMSO alone in this paradigm had no analgesic activity. Like morphine, the opioids levorphanol (ED_{50} 5.0 mM; CL 3.8, 7.8) and buprenorphine (ED_{50} 1.1 mM; CL 0.7, 1.5) were effective topical analgesics. Lidocaine also was active in the tail-flick assay (ED_{50} 2.6 mM; CL 2.0, 3.4), with a potency

greater than morphine. As expected, the free base of lidocaine was more potent than its salt. Combinations of a low dose of lidocaine with a low dose of an opioid yielded significantly greater than additive effects for all opioids tested. Isobolographic analysis confirmed the presence of synergy between lidocaine and morphine, levorphanol and buprenorphine. These studies demonstrate a potent interaction peripherally between opioids and a local anesthetic and offer potential advantages in the clinical management of pain.

Topical treatments offer many advantages over systemic drugs. By limiting the exposure of a drug to the periphery, central side effects can be markedly reduced. For opioids, this might decrease limiting side effects, such as sedation, respiratory depression, and nausea. Further limiting the drug to the actual site of action has even more advantages, by avoiding peripherally mediated side effects, such as constipation. In earlier studies, we demonstrated the activity of topical morphine in the radiant heat tail-flick assay after immersion in a dimethyl sulfoxide (DMSO) solution (Kolesnikov and Pasternak, 1999a). The analgesic actions seen with topical morphine were limited to the region of the tail exposed to the drug and were not seen in more proximal areas not exposed to the drug. DMSO alone was inactive in this paradigm. Other opioid ligands acting through kappa and delta receptors have activity peripherally in the radiant heat tail-flick assay as well (Kolesnikov et al., 1996a; Kolesnikov and Pasternak, 1999b). Thus, topical opioids might be useful in pain control.

Synergy is important in opioid action. First described between supraspinal and spinal sites (Yeung and Rudy, 1980), it has also been described between brainstem nuclei (Rossi et

al., 1993) and between peripheral and central sites (Kolesnikov et al., 1996b). Synergy has been observed between opioids of different classes (Horan et al., 1992; Adams et al., 1993; Rossi et al., 1994; He and Lee, 1998).

Opioid actions also can be modulated by nonopioid classes of drugs. For example, opioid tolerance can be prevented or reversed by *N*-methyl-D-aspartate (NMDA) antagonists (Trujillo and Akil, 1991; Ben-Elmehdi et al., 1992; Tiseo and Inturrisi, 1993; Elliott et al., 1994) and nitric oxide synthase inhibitors (Kolesnikov et al., 1992, 1993). Unfortunately, NMDA antagonists have proven difficult to use systemically due to their profound psychomimetic and dysphoric actions. These problems might be avoided by a topical approach. We were able to demonstrate in our topical paradigm that the combination of an NMDA antagonist with an opioid blocked tolerance to the opioid (Kolesnikov and Pasternak, 1999a,c). This activity of NMDA antagonists topically presumably would avoid the limiting side effects that preclude their use systemically.

Lidocaine, a local anesthetic, is active topically, by blocking sodium channels, a mechanism distinct from the opioids (Woosley and Funck-Brentano, 1988). Clinical studies have shown advantages to the combination of intrathecal lidocaine and opioids (Atanassoff et al., 1997; Saito et al., 1998a,b), leading us to question whether similar advantages might be seen topically. We therefore have examined the activity of topical lidocaine in the tail-flick assay alone and in combination with a number of opioids.

Received for publication April 17, 2000.

¹ This work was supported, in part, by a research grant (DA07241) and a Senior Scientist Award (DA00220) (to G.W.P.) and a Mentored Scientist Award (DA00405) (to Y.A.K.) from the National Institute on Drug Abuse, as well as a core grant (CA08748) from the National Cancer Institute and a grant from EpiCept Corporation.

ABBREVIATIONS: DMSO, dimethyl sulfoxide; NMDA, *N*-methyl-D-aspartate; CL, confidence limits.

2000

Topical Lidocaine/Opioid Analgesic Synergy

547

Materials and Methods

Male Crl:CD-1(ICR)BR mice (25–30 g, Charles River Breeding Laboratory, Bloomington, MA) were maintained on a 12-h light/dark cycle with food and water available ad libitum. Mice were housed in groups of five until testing. Opioids were generously provided by the Research Technology Branch of the National Institute on Drug Abuse (Rockville, MD). Lidocaine was purchased from Sigma Chemical Co. (St. Louis, MO). Lidocaine base was used in all experiments unless indicated otherwise.

Topical Administration. Drugs were administered topically and analgesia assessed as previously described (Kolesnikov and Pasternak, 1999a). In this procedure, the distal portion of the tail (2–3 cm) is immersed in a DMSO solution containing the indicated drugs for the stated time, typically 2 min (Kolesnikov and Pasternak, 1999a). Prior studies have documented that DMSO alone has no effect when tested in this manner in the radiant heat tail-flick assay (Kolesnikov and Pasternak, 1999a). Furthermore, DMSO provides an effective way of solubilizing a wide range of drugs and facilitating their transport through the skin. The onset of analgesia is rapid, with peak effects seen immediately after the removal of the tail from the treatment solution. Therefore, we tested animals immediately after termination of topical administration.

Radiant Heat Tail-Flick Test. Testing was performed on the portion of the tail immersed in the treatment solution, because the analgesic actions of agents administered in this manner are restricted to the exposed portions of the tail; proximal regions are not affected (Kolesnikov and Pasternak, 1999a). Antinociception, or analgesia, was defined quantitatively as a tail-flick latency for an individual animal that was twice its baseline latency or greater. Baseline latencies typically ranged from 2.5 to 3.0 s, with a maximum cutoff latency of 10 s to minimize tissue damage in analgesic animals. Group comparisons were performed with the Fisher's exact test. ED_{50} values were determined with the Bliss program (Finney, 1976; Umans and Inturrisi, 1981), as previously reported (Kolesnikov et al., 1999a).

Drug Interactions. Isobolographic analysis was used to determine drug interactions (Talaradia et al., 1997). ED_{50} values were determined for each agent alone. They were then tested together at various doses at a constant ratio based on their respective ED_{50} values. In the figures, all points represent ED_{50} values. Values on the axes represent the ED_{50} values for the indicated drug alone, and the line connecting them corresponds to simple additive interactions. Points lying below the line of additivity indicate synergism. Significance was assumed by the lack of overlap of the confidence limits of the combination value with the confidence limits of the line of additivity.

Results

Topical Lidocaine and Morphine Interactions. First, we assessed the activity of topical lidocaine using the same administration paradigm previously shown active for opioids and NMDA antagonists (Kolesnikov and Pasternak, 1999a). Earlier studies emphasized the importance of exposure time in the activity of morphine. Similarly, the analgesic response to lidocaine was dependent on the exposure time (Fig. 1A). The response from a constant concentration of lidocaine increased from 20% at 30 s to 70% at 2 min. Time action curves revealed a maximal response immediately after removal of the tail from the solution, with a gradual decrease to baseline levels within 20 min (Fig. 1B). This response was slightly shorter in duration than a morphine dose giving the same maximal response. A lower lidocaine dose gave both a decreased maximal response and a shorter duration of action.

Both the free base and salt of lidocaine were examined




Fig. 1. Time dependence of topical lidocaine analgesia. A, groups of mice ($n \geq 10$) were exposed to a fixed concentration of topical lidocaine (4.3 mM) for 30 s, 1 min, and 2 min and then were tested in the tail-flick assay immediately after termination of drug exposure. B, groups of mice ($n \geq 10$) were treated with lidocaine (4.3 or 2.15 mM) or morphine (15 mM) for 2 min and then tested in tail-flick assay at the indicated time over 30 min.

(Fig. 2). Both were active, but the salt was less effective and plateaued at a 50% to 60% response. As expected, the free base form of lidocaine was more active, achieving a 75% response. However, it displayed a biphasic dose-response curve, with increases in concentration beyond 20 mM revealing a progressive lowering of analgesic activity. Morphine also was active, as previously reported (Kolesnikov and Pasternak, 1999a), with a potency intermediate between the two




Fig. 2. Effects of topical lidocaine and morphine. Groups of mice ($n \geq 10$) were exposed to the indicated concentration of the free base of lidocaine, lidocaine HCl, or morphine for 2 min and tested immediately afterward.

TABLE 1

Analgesic potency of lidocaine and opioids alone and in combination

ED₅₀ values were determined from dose-response curves and presented with 95% confidence limits. For lidocaine, the ED₅₀ value was determined only from the initial portion of the curve. Combinations were also examined using increasing doses of a fixed ratio of the indicated drugs. ED₅₀ values were determined and presented with the 95% confidence limits. The relative potency of the various drugs in combination were compared with the same drug alone as a ratio. The fixed ratios were as follows: lidocaine/morphine, 0.5; lidocaine/buprenorphine, 2.4; lidocaine/levorphanol, 0.5.

Treatment	Lidocaine		Opioid	
	ED ₅₀ Value	Ratio	ED ₅₀ Value	Ratio
	mM		mM	
Lidocaine alone	2.5 (2.0, 3.4)		6.1 (4.3, 8.4)	
Morphine alone			1.1 (0.7, 1.5)	
Buprenorphine alone			5.0 (3.8, 7.8)	
Levorphanol alone			1.7 (1.2, 2.2)	3.6
Lidocaine/morphine	0.85 (0.6, 1.1)	2.9	0.94 (0.6, 1.6)	5.3
Lidocaine/levorphanol	0.47 (0.3, 0.8)	5.3	0.18 (0.12, 0.240)	6.1
Lidocaine/buprenorphine	0.44 (0.3, 0.6)	5.7		

forms of lidocaine (Table 1). The antagonist naloxone given alone was without effect.

Initially we assessed potential interactions between lidocaine and morphine using a fixed, low dose of each (Fig. 3A). Alone, lidocaine and morphine produced peak responses of only 20%. Together, their peak response was 80%, far greater than anticipated from simple additive interactions ($P < .004$). Comparing the areas under the curve gave even more dramatic differences. As anticipated, naloxone (1 mg/kg, s.c.),

given 20 min before agonist treatment, completely reversed the effects of the combination (data not shown).

To further assess the possibility of synergy, we next employed isobolographic analysis (Tallarida et al., 1997). A dose-response curve was generated using increasing doses of a fixed ratio of lidocaine/morphine. The ED₅₀ value fell well below the line of additivity, indicating synergism (Fig. 3B). The lack of overlap of the confidence limits of the combination value with those of the line of additivity confirmed its significance.

We also explored the relationship of lidocaine and morphine combinations by defining the ED₅₀ values of each agent alone and in combination with a fixed dose of the other rather than a ratio (Table 2). Low doses of morphine with little activity alone markedly enhanced the potency of lidocaine. The effect seemed to plateau, with little advantage seen by increasing the morphine concentration from 3 to 4.5 mM. Similar results were seen with the morphine dose-response curves. Again, a low dose of lidocaine facilitated morphine analgesia, with little additional effect seen after doubling the lidocaine concentration from 0.9 to 1.8 mM. Thus, the enhanced activity of the combination of the drugs was most evident at low concentrations of each.

Topical Lidocaine and Other Opioids. We next explored whether the synergy seen with morphine/lidocaine combinations extended to other opioids with other receptor mechanisms of action, including levorphanol and buprenorphine. Topically, levorphanol and buprenorphine both yielded full analgesic responses, with ED₅₀ values of 5.0 and 1.1 mM, respectively (Fig. 4; Table 1).




Fig. 3. Topical lidocaine and morphine interactions. A, groups of mice received either topical morphine (1.5 mM; $n = 10$) or lidocaine (0.9 mM; $n = 10$) alone or both together ($n = 20$). The combination was significantly ($P < .004$) more active at peak effect than the sum of two individual agents. B, using a fixed lidocaine/morphine ratio of 0.5, the ED₅₀ value of combination was determined with the 95% confidence limits. The presence of the ED₅₀ value below the line of additivity indicates the presence of synergy, confirmed by the lack of overlap between the 95% confidence limits for the drugs.

TABLE 2

Effects of fixed doses of morphine or lidocaine on the others analgesic potency

ED₅₀ values with 95% confidence limits were determined from at least three doses of topical lidocaine alone or with the indicated morphine concentration, or with topical morphine alone or with the indicated concentration of lidocaine.

	ED ₅₀	95% Confidence Limits	Shift
	mM		
Lidocaine alone	2.5	(2.0, 3.4)	
+Morphine 1.5 mM	1.0	(0.4, 1.8)	2.5
+Morphine 3.0 mM	0.8	(0.6, 1.1)	3.1
+Morphine 4.5 mM	0.7	(0.5, 0.9)	3.6
Morphine alone	6.1	(4.3, 8.4)	
+Lidocaine 0.45 mM	3.6	(2.6, 4.5)	1.7
+Lidocaine 0.9 mM	1.5	(0.9, 2.6)	4.1
+Lidocaine 1.8 mM	1.3	(0.6, 1.3)	4.7

2000

Topical Lidocaine/Opioid Analgesic Synergy

549




Fig. 4. Effects of topical buprenorphine and levorphanol. Groups of mice ($n \geq 10$) were exposed to the indicated concentration of the drug for 2 min and were tested immediately afterward.

Combinations of low doses of lidocaine and these opioids gave greater than additive analgesic actions (Fig. 5). The results with levorphanol closely resembled those of morphine, with the combination of low lidocaine and levorphanol doses giving a maximal response far beyond that expected by simple additive interactions ($P < .03$) as well as a prolonged duration far exceeding that of either alone (Fig. 5A). Although each drug alone had no effect beyond 5 min, together their response lasted for greater than 20 min. The effects of the combination of doses were readily antagonized by naloxone. The response to lidocaine alone (2.5 mM) was insensitive to naloxone (1 mg/kg, s.c.). (Data not shown.)

Buprenorphine and lidocaine gave similar results. The maximal responses of the two together were far beyond those anticipated by simple additive interactions (Fig. 5B). The duration of the response of the combination also markedly differed from that of either agent alone. Alone, each drug lasted less than 10 min. In contrast, the duration of the response of the combination was quite prolonged. The peak effect of the combination was 80% and persisted for 10 min. Analgesia could still be demonstrated after 45 min. Indeed, the duration of the response from the lidocaine/buprenorphine combination exceeded that seen with any of the other opioids tested. Naloxone significantly lowered the response of the combination.

Isobolographic Analysis of Lidocaine/Opioid Interactions. We next examined the combinations of the additional opioids isobolographically using dose-response curves with fixed ratios of the two drugs in combination (Fig. 6; Table 1). Combining levorphanol with lidocaine enhanced their relative potencies over 5-fold, which was more than the enhancement of morphine by lidocaine. Isobolographic analysis was consistent with synergy (Fig. 6A). Buprenorphine and lidocaine together shifted their individual ED_{50} values approximately 6-fold. Again, isobolographic analysis indicated synergy (Fig. 6B).

Discussion

Lidocaine is a widely used local anesthetic (Woosley and Funck-Brentano, 1988). It acts through the blockade of sodium channels, a mechanism distinct from the opioids. In the




Fig. 5. Effects of combinations of low doses of opioids with lidocaine. A, groups of mice ($n = 20$) received either topical lidocaine (0.9 mM) or levorphanol (1.8 mM) or the combination of the two for 2 min and were tested in the tail-flick assay over 30 min. Another group of mice ($n = 10$) received naloxone (1 mg/kg, s.c.) 20 min before the topical drug application and was tested in tail-flick assay. Naloxone significantly reduced the response. B, groups of mice ($n = 20$) received either topical lidocaine (0.9 mM) or buprenorphine (0.5 mM) or the combination of the two for 2 min and then were tested in the tail-flick assay over 60 min. Another group of animals received naloxone (1 mg/kg, s.c.) 20 min before the topical drug application. Naloxone significantly reduced the response.

current study, lidocaine was effective topically in the radiant heat tail-flick assay, working only on the portion of the tail exposed to the drug and with a potency greater than morphine. As anticipated, the free base was more effective than the salt, presumably due to its greater lipophilicity. However, its dose-response curve was biphasic, with concentrations greater than 20 mM giving a progressive decrease in response. The reasons for this are not clear, but it is interesting that lidocaine concentrations above 15 mM can be toxic to neurons in primary culture (Gold et al., 1998).

All of the opioids tested were effective topical analgesics. The activity of levorphanol and buprenorphine extends the activity to drugs working on opioid systems other than simply mu receptors. Levorphanol elicits analgesia through both mu and kappa₂ receptors (Moulin et al., 1988; Tive et al., 1992). Buprenorphine has a complex mechanism of action that is not entirely clear (Leander, 1987; Kamei et al.,




Fig. 6. Isobolographic analysis of lidocaine interactions with levorphanol and buprenorphine. A, using a fixed lidocaine/levorphanol ratio of 0.5, the ED₅₀ value of the combination with the 95% confidence limits was determined from the dose-response curve. The point falls below the theoretical line of additivity between the ED₅₀ values for each drug alone, indicating synergy. The lack of overlap between the 95% confidence limits for the drugs alone and the combination implies the synergy is significant. B, using a fixed lidocaine/buprenorphine ratio of 2.4, the ED₅₀ value of the combination with the 95% confidence limits was determined from the dose-response curve. The point falls below the theoretical line of additivity between the ED₅₀ values for each drug alone, indicating synergy. The lack of overlap between the 95% confidence limits for the drugs alone and the combination implies the synergy is significant.

1995a,b, 1997; Walker et al., 1995). Although it has high affinity for virtually all classes of opioid receptors in binding studies, it also has widely varying efficacies for the various classes of receptors. Typically, buprenorphine was particularly effective, with a potency 5-fold greater than that of morphine. The limited ability of naloxone to reverse the combination of buprenorphine and lidocaine implies that at least a portion of the response from buprenorphine was evoked from non- μ -opioid receptors.

Opioid analgesic synergy has been well established. Initially, it was observed among regions simultaneously exposed to opioid (Yeung and Rudy, 1980; Rossi et al., 1993, 1994; Kolesnikov et al., 1996b), followed by the demonstration of synergy between different classes of opioids (Adams et al., 1993). Morphine also has been reported to demonstrate synergy with lidocaine centrally (Saito et al., 1998a,b). We now

find synergy peripherally between topical opioids and a local anesthetic.

The combination of a low dose of morphine and lidocaine clearly revealed activity far beyond simple additive interactions, as did similar studies with the other opioids. These strongly suggested synergy among the opioids with lidocaine. This was not unexpected. Synergistic interactions might be more likely when drugs act on different mechanisms, as shown here with the opioids and lidocaine. Isobolographic analysis confirmed synergy between lidocaine and the opioids. The most impressive interaction was between buprenorphine and lidocaine, which had the greatest potentiation and the longest duration of action. However, it is not clear whether this resulted from its receptor selectivity or other factors such as its greater lipophilicity, which would enhance its ability to become diffused through the skin.

The demonstration of synergy between lidocaine and more than one opioid receptor ligand deserves more study. It will be of interest to define the opioid receptor mechanisms involved more clearly. However, even without a full understanding of how these agents interact, the demonstration of topical synergy between a local anesthetic and opioids opens many clinical possibilities in pain management.

References

- Adams JU, Tallarida RJ, Geller EB and Adler MW (1993) Isobolographic superadditivity between δ and μ opioid agonists in the rat depends on the ratio of compounds, the μ agonist and the analgesic assay used. *J Pharmacol Exp Ther* 266:1261-1267.
- Abanasoff PG, Brull SJ, Printsev Y and Silverman DG (1997) The effect of intradermal administration of lidocaine and morphine on the response to thermal stimulation. *Anesth Analg* 84:1840-1843.
- Ben-El-Mechaieq H, Marek P, Vaccarino AL, Mogil JS, Sternberg WF and Liebeskind JC (1992) The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. *Brain Res* 576:304-308.
- Elliott K, Minami N, Kolesnikov YA, Pasternak GW and Inturrisi CE (1994) The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, N^G-nitro-L-arginine, attenuate analgesic tolerance to the μ -opioid morphine but not to kappa opioids. *Pain* 58:69-75.
- Finney DJ (1976) A computer program for parallel line bioassays. *J Pharmacol Exp Ther* 198:497-506.
- Gold MS, Reichling DB, Hampf RF, Drasner K and Levine JD (1996) Lidocaine toxicity in primary afferent neurons from the rat. *J Pharmacol Exp Ther* 255:413-421.
- He L and Lee NM (1998) Delta opioid receptor enhancement of μ opioid receptor-induced antinociception in spinal cord. *J Pharmacol Exp Ther* 285:1181-1186.
- Horan P, Tallarida RJ, Haaseth RC, Matsunaga TO, Hruby VJ and Parreca F (1992) Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: Supra- and sub-additivity. *Life Sci* 50:1535-1541.
- Kumci J, Saitoh A, Morita K and Nagase H (1996a) Antagonistic effect of buprenorphine on the antinociceptive effect of morphine is mediated via the activation of μ_1 -opioid receptors. *Life Sci* 57:PL231-PL235.
- Kamei J, Saitoh A, Suzuki T, Misawa M, Nagase H and Kasuya Y (1995b) Buprenorphine exerts its antinociceptive activity via μ_1 -opioid receptors. *Life Sci* 56:PL285-PL290.
- Kamei J, Sodeyama M, Tada M, Suzuki T and Nagase H (1997) Antinociceptive effect of buprenorphine in μ_1 -opioid receptor deficient CXBK mice. *Life Sci* 60: PL333-PL337.
- Kolesnikov Y, Jain S, Wilson R and Pasternak GW (1996a) Peripheral kappa₁-opioid receptor-mediated analgesia in mice. *Eur J Pharmacol* 310:141-143.
- Kolesnikov YA, Jain S, Wilson R and Pasternak GW (1996b) Peripheral morphine analgesia: Synergy with central sites and a target of morphine tolerance. *J Pharmacol Exp Ther* 279:502-506.
- Kolesnikov Y and Pasternak GW (1999a) Topical opioids in mice: Analgesia and reversal of tolerance by a topical N-methyl-D-aspartate antagonist. *J Pharmacol Exp Ther* 290:247-252.
- Kolesnikov YA and Pasternak GW (1999b) Peripheral orphanin FQ/ nociceptin analgesin in the mouse. *Life Sci* 64:2021-2028.
- Kolesnikov YA and Pasternak GW (1999c) Peripheral blockade of topical morphine tolerance by ketamine. *Eur J Pharmacol* 374:R1-R2.
- Kolesnikov YA, Pick CG, Ciszewski G and Pasternak GW (1998) Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor. *Proc Natl Acad Sci USA* 95:5162-5166.
- Kolesnikov YA, Pick CG and Pasternak GW (1992) N^G-Nitro-L-arginine prevents morphine tolerance. *Eur J Pharmacol* 231:339-340.
- Leander JD (1997) Buprenorphine has potent kappa opioid receptor antagonist activity. *Neuropharmacology* 36:1445-1447.
- Moulins DE, Ling GSF and Pasternak GW (1988) Unidirectional analgesic cross tolerance between morphine and levorphanol in the rat. *Pain* 38:233-239.

2000

Topical Lidocaine/Opioid Analgesic Synergy 551

- Rossi GC, Pasternak GW and Bodnar RJ (1993) Synergistic brainstem interactions for morphine analgesia. *Brain Res* 624:171-180.
- Rossi GC, Pasternak GW and Bodnar RJ (1994) μ and δ opioid synergy between the periaqueductal gray and the rostro-ventral medulla. *Brain Res* 665:85-93.
- Saito Y, Kaneko M, Kirihara Y, Sakura S and Kosaka Y (1998a) Interaction of intrathecally infused morphine and lidocaine in rats (part I): Synergistic antinociceptive effects. *Anesthesiology* 89:1456-1463.
- Saito Y, Kaneko M, Kirihara Y, Sakura S and Kosaka Y (1998b) Interaction of intrathecally infused morphine and lidocaine in rats (part II): Effects on the development of tolerance to morphine. *Anesthesiology* 89:1464-1470.
- Tallada RJ, Stone DJ, Raffa RB and Stone DJ Jr (1997) Efficient designs for studying synergistic drug combinations. *Life Sci* 61:PL417-PL425.
- Tiseo P and Inturrisi CE (1993) Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate antagonist LY274614. *J Pharmacol Exp Ther* 264:1090-1096.
- Tive LA, Ginsberg K, Pick CG and Pasternak GW (1992) Kappa₂ receptors and levorphanol-induced analgesia. *Neuropharmacology* 31:851-856.
- Troville KA and Akil H (1991) Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. *Science (Wash DC)* 251:85-87.
- Umans JG and Inturrisi CE (1981) Pharmacodynamics of subcutaneously administered diacetylmorphine, 6-acetylmorphine and morphine in mice. *J Pharmacol Exp Ther* 218:409-415.
- Walker EA, Zernig G and Woods JH (1995) Buprenorphine antagonism of μ opioids in the rhesus monkey tail-withdrawal procedure. *J Pharmacol Exp Ther* 273:1345-1352.
- Woolsey RL and Funch-Brentano C (1968) Overview of the clinical pharmacology of antiarrhythmic drugs. *Am J Cardiol* 61:61A-69A.
- Yeung JC and Rudy TA (1980) Multiplicative interaction between narcotic agonists expressed at spinal and supraspinal sites of antinociceptive action as revealed by concurrent intrathecal and intracerebroventricular injections of morphine. *J Pharmacol Exp Ther* 215:633-642.

Send reprint requests to: Gavril W. Pasternak, M.D., Ph.D., Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021. E-mail: pasternag@mskmail.mskcc.org